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Abstract 
Aims: To examine the expression of four oncoproteins, p53, c-myc, c-fos 
and c-erbB2 in association with normal cervical specimens, preinvasive and 
invasive cervical neoplasm and evaluate oncogenes overexpression in the 
pathogenesis and progression of cervical cancer. 
Methods: Immunohistochemical staining for p53, c-myc, c-fos and c-erbB2 
was performed in 95 formalin-fixed, paraffin-embedded cervical specimens 
including 8 normal cervical specimens, 30 specimens of cervical 
intraepithelial neoplasia (CIN) and 57 invasive cervical cancers. Microwave 
oven heating was used for antigen retrieval. In addition, 30 specimens of 
invasive cervical cancer were also investigated for c-myc gene mutation by 
polymerase chain reaction single-strand conformation polymorphism (PCR-
SSCP). The data was statistically analyzed using Chi-square test and 
Fisher's Exact test. 
Result: p53 immunoreactivity was seen in 6 of 30 (20%) CIN specimens, 
22 of 57 (38 %) cervical cancer but none of the eight normal specimens. A 
marginal association was found between p53 overexpression in cervical 
cancer and age of patient (p=0.05). No significant association was found 
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between p53 expression and clinical parameters. However, in the group of 
adenocarcinoma of cervix, 5 out of 15 (33%) specimens were 
overexpressed with the p53 oncoprotein. Among those five cases with p53 
overexpression，4 out of 5 (80%) cases were died of the disease within one 
year follow-up. c-erbB2 immunoreactivity was seen in 3 normal (37%) 
specimens, 26 (87%) specimens of CIN and 54 (94%) specimens of 
invasive cervical cancer. No association was found between c-erhB2 
overexpression and clinical and pathological parameters. 3 of 30 specimens 
(10 %) of CIN and 20 of 33 (60 %) specimens of invasive cervical cancer 
but none of the eight normal specimens were overexpressed with c-fos 
protein. No significant association was found between c-fos overexpression 
and clinical and pathological parameters, c-myc immunoreactivity was 
detected in 2 of 8 (25%) normal specimens, 20 of 30 (67%) CIN and 47 of 
57 (82%) specimens of invasive cervical cancer. The expression of c-myc 
had a marginal association with pathological grade of cervical cancer 
(p=0.05). In addition, the expression of c-myc was associated with clinical 
stage in the group of squamous cell carcinoma of cervix (p<0.05). No 
mutation of c-myc was detected by PCR-SSCP in all 30 cervical cancer 
specimens. 
Conclusions: The results of this study suggested that overexpression of c-
erhB2 and c-myc might be associated with the pathogenesis of cervical 
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cancer while overexpression of Q-fos and tumour suppressor gene p53 was 
associated with the progression of cervical cancer. In addition, 
overexpression of the p53 protein might be associated with poor outcome 
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Cervical cancer is the second common gynecological malignancy in 
woman worldwide after cancer of the breast. Each year，there are 
approximately 465,000 new cases of invasive cancer of cervix diagnosed 
and in excess of 200,000 deaths from the disease all over the world. In 
Hong Kong, there were 2311 cases of malignant neoplasm of cervix uteri 
being treated in-patient in Hong Kong in 1993-1994. Among them 144 
women died of the disease. Mortality rate was 5 per 100,000 in Hong Kong 
(Chan, 1994). 
The disease occurred most often in women between age 45-60 with 
a peak incidence between the age of 50-55. 95% of untreated patients will 
die by the end of the fifth year after the diagnosis. There are many risk 
factors correlated to the pathogenesis of the cervical cancer. Some are well 
established and some are still being investigated. Important risk factors 
include sexual and reproductive factors, smoking, infectious agents such as 
HPV and HSV-2，immunosupressive conditions and the intake of oral 
contraceptive pills. 
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It has been realized for many years that cancer has a genetic 
component (Foulds 1951). Evidences arise from large families with slightly 
higher than expected incidence of all types of cancer and from families in 
which some members have a greater chance of developing cancer. Certain 
types of tumors, such as retinoblastoma (RB) and Wilms tumor (WT) 
appear to be inherited as autosomal dominant traits (Knudson et al.,1971). 
Other genetic disorders may increase the chances of mutation for all genes 
and indirectly contribute to cancer (Palla-Favera et al.，1982; Knudson et 
al., 1985). 
All cancer cells have a common feature. It is the lost of normal 
growth control mechanisms resulting in uncontrollable proliferation of 
neoplastic cells. Tumour formation is a multistep process. The oncogene 
and tumour suppressor genes paradigm developed over the past decade has 
proved to be particularly powerful in explaining the generation of cancer at 
the molecular level (Klein et al., 1985). Plenty of evidences discovered in 
recent years demonstrated that activated oncogenes and their normal 
cellular precursors, proto-oncogenes, encoded molecules that were 
involved at various stages of growth signaling pathways (Wynford-Thomas 
1991). 
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A general definition of oncogene is a gene of which abnormal 
expression or altered gene product directly lead to a transformed 
phenotype. The precursors to oncogenes (proto-oncogenes) produce 
molecules which are intimately involved in the control of cellular 
proliferation or differentiation. They can be growth factors, growth factor 
receptors, signal transducers or nuclear factors and appear to play an 
important role in activating cell growth at a number of stages in the 
signaling pathway. Another important class of cancer gene is tumour 
suppressor genes which also contribute to the development of cancer. 
Tumour suppressor genes were discovered through the study of inherited 
cancer susceptibilities. The inactivation or loss of expression of these genes 
may also produce tumour (Wynford-Thomas, 1991). One of the tumour 
suppressor gene is p53 gene and mutation of which can be found in up to 
50% of all human cancers (Bartek et al., 1991; Hollstein et al., 1991). 
Protein product of p53 gene apparently inhibits cell division and blocks 
cells progression in the cell cycle (Marx, 1993). Other possible roles of 
tumour suppressor gene include (1) contact inhibition receptors, (2) 
secreted factor that are negative regulators of the cells own growth and (3) 
secreted factors which induce end-stage differentiation of other cells. 
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In the past few years, by applying the techniques of molecular 
technology to the study of cancer, understanding of the process of cervical 
cancer in molecular level was increased (Pinion et al., 1991). Molecular 
techniques have been used to identify oncogenes and tumour supressor 
genes and also to examine their role in the development of different kinds 
of malignant tumours. Detection of oncogene activation and tumour 
suppressor gene inactivation might be useful to make early diagnosis and 
predict prognosis of cancer (Wynford-Thomas, 1991). 
Immunohistochemistry techniques are widely used in studying 
expression of oncoproteins in tissue structures. This technique permits 
visualization of immunologically detectable oncoprotein (antigens) in tissue 
sections. Both morphology and immunophenotype of a tissue or neoplasm 
could be observed at the same time (Magrisso et al., 1993) 
In this study, immunohistochemical and molecular technique were 
used and this study involved the following objectives : 
(1) To examine the expressions of four oncoproteins, p53, c-myc，c-fos and 
c-erbB2 in normal cervix tissue, preinvasive cervical lesions and invasive 
cervical neoplasm by immunohistochemistry. 
(2) To detect any mutation of the c-myc gene by PCR-SSCP method and 
compare with the result of immunohistochemistry. 
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(3) To evaluate the prognostic value on overexpression of oncoprotein in 
cervical neoplasm. 
(4) To investigate these oncoproteins (p53, c-myc c-fos and c-erhB2) 
overexpression and the relationships of these findings to certain clinical 




2.1 Anatomy of the cervix 
The uterus is a pelvic organ situated between the bladder and 
rectum. Uterus of adult is 7.5 cm long and weighs about 70g . It is a thick-
walled, pear-shaped hollow muscular organ which can be divided into 
flmdus，corpus and cervix. The body and the cervix are separated by a 
narrow area which becomes the lower segment in pregnancy. The cervix 
protrudes into the vagina through the anterior wall of the vaginal vault 
which divides it equally into an upper (supravaginal) and lower (vaginal) 
portion. The anterior lip of the cervix lies at a lower level than its posterior 
lip. The endocervical cannel is lined by columnar epithelium and is 
originated from the Mullerian duct. The epithelium covering the ectocervix 
and the vagina derives from the urogenital sinus. During certain periods of 
life, especially late fetal development, adolescence and pregnancy, the 
columnar epithelium at the squamous-columnar junction undergoes 
squamous metaplasia and becomes squamous epithelium. The squamo-
colummar junction therefore advances itself towards the cannel. The area 
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situated between the new squamocolummar junction and the viginal 
squamocolummar junction is called transformation zone. This is a dynamic 
area with active cellular activities. If the cervix was exposed to 
tumourogenic factors, the normal metaplastic activities may turn into a 
neoplastic process instead and that explains why 95% of cervical carcinoma 
arises in this area. Evidences show that the extent and tendency to 
abnormality of the transformation zone may be related to early sexual 
activity and pregnancy (Brinton et al., 1986). 
2.2 Classification 
2.2.1 Cervical intraepithelial neoplasia (CIN) 
In 1953, Reagan, Seideman & Saracusa used the term dysplasia to 
describe changes of differentiation of the squamous epithelium as the 
preinvasive disease of the cervix. It was further classified as mild dysplasia, 
moderate dysplasia and severe dysplasia. The definition was imprecise and 
the assessment was subjective because displasia and carcinoma in situ were 
treated as two different diseases while the epithelial changes of the cervix 
exhibited a continues spectrum of abnormalities (Richart, 1965). 
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In 1967, Richart introduced a new system of nomenclature, cervical 
intraepithelial neoplasia (CIN), to clarify the different degrees of 
differentiation of the preinvasive disease in a continuous spectrum. It has 
been customary to divide CIN into three grades. CIN 1 corresponds to 
mild dysplasia and CIN 2 corresponds to moderate dysplasia while CIN 3 
referred to severe dysplasia and carcinoma in situ. The CIN grading is 
determined by the degree of differentiation, nuclear abnormalities and 
mitotic activity of the nucleus. Nuclei in CIN are characterized by 
enlargement, hyperchromasia, chromatin clumping and irregularities in size 
and shape. They are the most important criteria for making the diagnosis of 
CIN and for determining its grade (Fu，Reagan & Richart 1981 & 1983; 
Mourits et al., 1992). 
In normal cervical epithelium, the epithelium is uniform in pattern 
and cytology. The cells mature progressively as they move toward the 
surface. Little or no mitotic activity is seen in normal epithelium of the 
cervix and mitotic figures are confined to the parabasal layer. As the grade 
of CIN increases, the number of mitotic figures also increases and they may 
be present at any level in the epithelium. The gradings of CIN may 
therefore be characterized as follows: 
(1) CIN 1 
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Nuclear abnormalities are mild and are most marked in the basal 
third of the epithelium. Mitotic figures are present but not numerous and 
confined to the basal third of the epithelium. The upper two-thirds of the 
epithelium shows good differentiation. The cells in the lower third or less of 
the epithelium show no evidence of cytoplasmic differentiation and have a 
high nucleocytoplasmic ratio while those in the middle and upper thirds of 
the epithelium show evidence of maturation with a decreased 
nucleocytoplasmic ratio. 
(2) CIN 2 
Nuclear abnormalities are more severe than in CIN 1 and more 
abnormalities can be seen closer to the surface of the epithelium. Mitotic 
figures and high necleocytoplasmic ratio are seen in the basal two-thirds of 
the epithelium. The upper one-thirds of the epithelium shows maturation 
and differentiation. 
(3) CIN 3 
Marked nuclear abnormalities are present throughout the whole 
thickness of the epithelium. Mitotic figures are present at all levels of the 
16 
epithelium. Maturation and differentiation are either completely absent or 
confined to the superficial third of the epithelium. Atypical pleomorphic and 
sometimes bizarre cells are seen. The nucleus are frequently presented with 
markly hyperchromasia, nucleomegaly and abnormal chromatin 
organization through out the whole thickness of the epithelium (Buckley et 
al., 1982). 
Another diagnostic system for histologic terminology for cytology 
was recommended by a group meeting at the National Cancer Institute 
(National Cancer Institute workshop, 1988，1989 & 1992). They grouped 
flat condyloma and low-grade CIN (CIN 1) in a single termed. “ low-grade 
squamous intraepithelial lesion" (LGSIL), and combined CIN 2 and CIN 3 
into "high-grade squamous intraepithelial lesion" (HISIL). In the United 
States, squamous intraepithelial lesion “ SIL" is most commonly used by 
cytologists and the term "CIN" is most commonly used for histologic 
lesions (Richart, 1990). 
2.2.2 Cervical cancer 
(1) Microinvasive carcinoma 
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Microinvasive squamous carcinoma is an early invasive squamous 
carcinoma which is not visible clinically and the diagnosis is only made 
histologically (Roche et al., 1975; Sedlis et al., 1979). According to the 
1988 modification of the International Federation of Gynaecology and 
Obstetrics ( FIGO )，it is regarded as stage lA (Table 2.1). It is a 
histological diagnosis which should be made on a large biopsy, preferably a 
cone biopsy that removes the whole lesion. It can be subdivided into lAl 
and 1A2. In lAl, early stromal invasion in which invasive buds are present 
either in continuity with an in situ lesion, or apparently separated cell not 
more than 1 mm from the nearest surface or crypt basement membrane. In 
1A2, Lesions of greater dimensions than stage measurable lesions should be 
measure. The upper limit of the measurement should not show a depth of 
invasion of more than 5 mm taken from the base of the epithelium, either 
surface of grandular, from which it originates, and a second dimensions 
should be classified as stage IB (Kurma, 1994). 
(2) Invasive carcinoma 
Cervical cancer represents about 10% of all cancers in women and 
25 to 45% of female genital cancers. Invasive cervical cancer consists of 
about 85% of squamous cell carcinoma, 15% of adenocarcinoma and 
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adenosquamous carcinoma (Scully et al., 1994). Sarcomas and metastatic 
tumours are rare. 
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Table 2.1 
1988 modification of International Federation of Gynecologists and 
Obstetricians (FIGO) staging of carcinoma (Kurma, 1994). 
Stage 
0 Carcinoma in situ, intraepithelial carcinoma 
1 The carcinoma is strictly confined to the cervix (extension to the 
corpus should be disregarded) 
1A Preclinical carcinomas of the cervix, that is, those diagnosed only by 
microscopy 
1 Al Minimal microscopically evident stromal invasion 
1A2 Lesions detected microscopically that can be measured. The upper 
limit of the measurement should not show a depth of invasion of 
more than 5 mm taken from the base of the epithelium, either surface 
of glandular, from which it originates, and a second dimensions ’ the 
horizontal speed, must not exceed 7mm; larger lesions should be 
classified as stage IB 
IB Lesions of greater dimensions than stage 1A2, whether seen 
clinically or not. Performed space involvement should not alter the 
staging but should be specifically recorded so as to determine 
whether it should affect treatment decisions in the future 
2 The carcinoma extends beyond the cervix but has not extended to 
the pelvic wall. The carcinoma involves the vagina but not as far as 
the lower third 
2A No obvious parametrial involvement 
2B Obvious parametrial involvement 
3 The carcinoma has extended to the pelvic wall. On rectal 
examination, there is no cancer-free between the tumor and pelvic 
wall; the tumor involves the lower third of the vagina; all cases with 
hydronephrosis or nonfunctioning kidney are included unless they 
are known to be due to other causes 
3 A No extension to the pelvic wall 
3B Extension to the pelvic wall and/or hydronephrosis or 
nonfunctioning kidney 
4 The carcinoma has extended beyond the true pelvic or has clinically 
involved the mucous of the bladder or rectum; a bullous edema as 
such does not permit a case to be allotted to stage 4 
4 A Spread of the growth to adjacent organs 
4B Spread to distant organs 
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2.2.3 Incidence and cervical screening 
In 1993-1994, there were totally 2945 women death of malignant 
neoplasms in Hong Kong (Chan, 1994). Among them, 141 were died of 
malignant neoplasm of cervix uteri. It is the second common cause of 
cancer death among women while breast cancer is the commonest (313). 
The number of CIN cases detected in hospitals has been increasing and the 
age of patients with CIN appears to be decreasing. These may be the result 
of the cervical screening program in the past ten years.. Since 1970，the 
Hong Kong Family Planning association has recommended women after the 
age of 20 to attend the family planning clinic yearly for regular 
gynaecologic examinations and Papanicolaou test (Pap smear). Those with 
moderate or severe Papanicolaou test are referred for colposcopic 
evaluation. A borderline or mildly dyskaratic smear should be managed by 
repeat smear at six months. The colposcopy was first introduced in 
Germany. It allowed Gynaecologic doctors to examine the illuminated 
cervix and lower genital tract under magnification. The two most common 
indication for colposcopy are: 
1. To locate the cervix in patients with abnormal smear. It can be 
combined with endocervical curettage and punch biopsy if necessary. 
2. To examine a clinically suspicious cervix, even in the presence of a 
normal smear. 
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Iodine and Acetic acid are used to identify cervical lesions. Women 
who had acetic-white area are suspected of cervical dysplasia (Le et al., 
1993). Those with atypical (abnormal) colposcopic appearances, possible 
acetic-white change, leukoplakia, punctation, mosaic pattern, warty 
characteristics, atypical vessels, iodine non-staining, are suspicious of 
precancerous changes. In all these situation, biopsy must be done to 
confirm the diagnosis. 
Although a large number of studies support that more advanced 
lesion of CIN (CIN 3) are more likely to persist or progress to cervical 
cancer than CIN l(Richart, 1967; Heinzl et al., 1982; Campion et al., 1986; 
Greenberg, 1992), there is no method for predicting which patient will 
remain as CIN or progress to invasive cancer. 
Because cancer of cervix is preceded by preinvasive lesion for many 
years (Mclndoe et al., 1984) and the cure rate for patient with precancer 
disease after treatment is nearly 100% (Prendiville et al., 1989; Wright et 
al.，1992). So, it is important to advocate the female population to 
participate the cervical screening program. 
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2.2.4 Etiology of cervical cancer 
2.2.4.1 Sexual and reproductive factors 
In a case-control study, risk factor of cervical cancer was related to 
age at first intercourse (Brinton et al., 1987). The patients suffering from 
carcinoma of cervix were twofold differential between those with first 
intercourse before the age of 16 and the age of 20 risk of developing cancer 
of cervix. It was also related to lifetime number of sexual partners (Brinton 
et al., 1987). In addition, there was association between the number of 
deliveries and carcinoma of cervix. A study carried out in America showed 
a fourfold increase in risk of invasive cervical cancer in patients with 12 or 
more delivery than those with no or one delivery (Brinton et al., 1987; 
1989; Herrero et al., 1990). 
2.2.4.2 Smoking as a risk factor 
In recent years, cigarette smoking has emerged as an important 
etiologic factor for cervical cancer. Wright and co-workers found a graded 
relationship between smoking and cervical cancer after exclusion other 
variables of risk factors. Harris and co-workers also found a graded 
association between smoking and increasing severity of dyskaryosis which 
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persisted. The effect was especially apparent in the development of 
squamous cell of cervix rather than adenocarcinoma or adenosquamous 
cancer of the cervix (Brinton et al., 1986). 
2.2.4.3 Male partner contribution 
Although there were not many evidences implicating male factors 
contribution in the development of carcinoma of cervix, a report showed 
the geographic clusters of cervical cancer among the wives of men with 
penile cancer (Buckley et al., 1981). The sexual histories of the husbands of 
the cervical cancer patients may be important. A case control study 
reported that husbands of cervical cancer significantly has large number of 
sexual partners than husbands of controls (Brinton et al., 1989). 
2.2.4.4 Human papillomaviruses and cervical cancer 
In the late 1970，s Zur Hausen firstly suggested that HPV might be 
associated with cervical cancer. Many epidemiological, clinical, 
pathological, and molecular studies have demonstrated the existence of 
HPVs in cervical cancers and their precursor lesions (CIN) (Meanwell et 
al., 1987; Wright et al., 1990; Schiffman, 1992). 
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With the application of molecular techniques, several groups of 
investigators demonstrated that specific types of HPV DNA could be 
identified by Sourthen blot hybridization and PGR in most invasive 
carcinoma of the cervix and CIN (Lancaster et al., 1986; Lungu et al., 
1992). 
Papillomaviruses were classified as members of the family 
Papovaviridae. They are characterized by a double-standed DNA genome 
of approximately 8,000 base pairs in length. In humans, papillomaviruses 
infection may occur on the skin and mucous membranes in the conjunctiva, 
oral cavity, larynx, tracheobronchial tree, esophagus, bladder, anus and 
genital tract of both sexes. 
More than 60 types of HPV have been isolated and they have been 
classified into three "oncogenic risk" groups (Lorincz et al., 1992). The low 
oncogenic risk group includes HPVs 6 and 11. They are usually associated 
with condyloma acuminata of the anogenital tract and only occasionally 
associated with CIN 1 but rarely associated with CIN 2,3 and almost never 
associated with invasive squamous cell carcinomas of the cervix. The 
intermediate oncogenic risk HPV includes types 31,33,35,51 and 52. They 
are frequently associated with all grade of CIN but only occasionally 
associated with invasive cancer. The high oncogenic risk HPV types are 
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16,18,45 and 56. They are frequently associated with invasive squamous 
cell carcinoma of the cervix (Gallup et al., 1985). 
The mechanisms of how HPV induces malignant transformation 
have been proved by in vitro studies using tissue culture cells. The E6 and 
E7 open read frames (ORFs) represent the principal transforming genes of 
HPV (Bedell MA et al., 1987,1989) In HPV type 16 and 18, there were 
overexpressions of E6 and E7 ORFS in established tissue culture cell lines. 
These can cause malignant transformation but the situation is rarely occur 
in low oncogenic risk HPV such as HPV 6 and 11. In tissue culture cell 
line，both E6 and E7 must be present in the transformation. It suggests that 
the over or unregulated expression of these genes is required for the 
maintenance of the transformed malignant phenotype. 
Tlie actual mechanism of how HPV induces malignant 
transformation is a complex subject. Although the association of high risk 
HPV infection with invasive cervical cancer provides compelling evidence 
for HPV as a causative factor, several lines of studies suggest that HPV 
infection alone was insufficient to bring about the fully malignant 
phenotype. Although infection with high risk HPV type was common in 
patient with cervical cancer, only a small percentage of infected woman 
developed invasive cervical cancer. In addition, most patients develop 
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cancer after initial infection of HPV 20 or more years. These findings 
suggested that in addition to high-risk HPV infection, other events are 
required for the development of cervical cancer. This requires other genetic 
alteration to the development of the disease and tumorigenesis is a 
multistep process. 
Oncogenes and tumour suppressor genes may also pay a important 
role in the development of cervical cancer. For example, the inactivation of 
p53 tumour suppressor gene, either by gene mutation or overexpression, 
are also proved to be correlated to the pathogenesis of cervical cancer. The 
p53 protein may bound HPV-16/18 E6 protein in the cell cytoplasm and 
lead to loss of the tumour-supressor function in the nucleus (Liang et al., 
1993). 
2.2.4.5 Oral contraceptive pill 
Recent studies on the relationship of oral contraceptive pills and the 
pathological changes of the cervix found that an increased risk of 
approximately twofold for users of oral contraceptive pill for five or more 
years (Brinton, 1986; 1990; Beral et al., 1988). In others studies, pills user 
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was associated with the development of adenocarcinomas of the cervix 
(Korhonen et al., 1980). 
2.2.4.6 Oncogenes and tumour suppressor gene 
The growth and differentiation of normal cells are a highly regulated 
process so that normal cells can grow and stop growing at appropriate 
times. This phenomenon is supported by cellular response to both external 
and internal signal. Cancer cells differ from normal cells in many important 
characteristics. They tend to loss normal regulation, increase invasive ability 
and continue to proliferate without undergoing differentiation. These 
changes in the behavior of cancer cells may be due to changes in the genetic 
material within the cell. 
It was proposed that cancer were the result of infection of a cell 
with a virus that carried a cancer-causing gene, oncogene (Bishop, 1983). 
Further studies revealed that the oncogenes carried by the tumour viruses 
were normal cellular genes that had been incorporated into the viral 
genome. These genes were able to induce malignant transformation either 
in tissue culture or in animals (Bishop, 1983). Furthermore in the 
tomurogenesis in other situation such as post UV light exposure, contact 
with other chemical cancinogenes may also result in the alternation of the 
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genes. So the concept of an oncogene had been expanded to include any 
gene that can produce or alter the malignant phenotype of a cell. To 
differentiate an oncogene from its normal counterpart, the normal gene is 
referred to as a proto-oncogene. Molecular research performed in the last 
two decades has identify dominantly acting DNA sequences whose 
expression associates with conversion of normal cells to cancer cells. These 
DNA sequences are known as oncogenes and were first identified in the 
genomes of acutely transforming rodent and avian retroviruses, which 
efficiently transform cells and induce tumors in vivo within 2 to 3 weeks. 
The presentation of oncogenes have also been identified and based on the 
ability of some oncogenes to change the growth characteristics of murine 
fibroblast cell line NIH/313 (Cooper et al, 1980). These cells normally stop 
growing when the culture dish surface has been completely covered by 
cellular monolayer of propagated cells. However, when purified tumour 
DNA is transfected into these cells, a few cells may take up and express an 
oncogene and the growth of these cells is no longer inhibited by contact 
with their neighbours. The finding that purified preparation of some 
oncogenes could be transfected into freshly cultured normal cells and lead 
to the expression of a malignant phenotype has provided important linkage 
between oncogenes and cancer. Experimental studies had revealed that 
oncogenes also appear to be regulated in a specific manner during fetal 
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development, and that transcription levels for different cellular oncogenes 
vary in the same tissues at different stages of development. 
(1) Classification 
There are more than 75 proto-oncogenes now thought to be present 
in the normal genome of every mammalian cell (Bishop, 1991). Functions 
of most oncogenes and their corresponding protein products are not well 
understood but the biochemical activities of several oncogene products 
have been recognized to correspond to proteins known to play important 
roles in the regulation of growth. The important function pathways are 
growth factors, their receptors, cytoplasmic protein that transfer the growth 
message between the cytoplasmic and the nucleus with the specific nucleus 
proteins that involve in the activation of proto-oncogene to become 
malignant" transformation of a normal cell. 
Proto-oncogenes can be classified into five major categories. The 
first and largest class of proto-oncogenes encodes protein kinase. This 
group of proto-oncogenes can be further subclassified into two functional 
groups: those encoding tyrosine-specific kinases (including src, abl, fes, 
fgr’ ros, rel, yes, and syn) and those that encode proteins that have a 
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kinase-like domain which do not possess detectable tyrosine kinase activity 
/« vitro (which include raf, pks, kit, mos, and sea) (Brodeur, 1987). 
The second class of proto-oncogenes is the ras family and consists 
of H-ms, K-ras, and N-roy. The ras family has different degrees of 
homology in their effector regions. Each of the genes in the ras family is 
composed of four coding exons with identical intron spacing, and each 
encodes a 21,000-d polypeptide (p21) and bind GTP and GDP and has a 
GTPase and autokinase activity. It is located on the plasma membrane 
when active. 
The third class of proto-oncogenes encodes growth factors 
themselves. This group includes the int and sis genes. The int-\ gene was 
identified in mammary neoplasms and encodes a protein in the fibroblast 
growth factor family. The proto-oncogene v-sis is derived from genes 
encoding platelet-derived growth factor (PDGF) and has 92% homology 
with the nonglycosylated p-chain of PDGF. 
The fourth class encodes polypetide growth factor receptors or 
proteins with the characteristic transmembrane structure of a growth factor 
receptor. This group of proto-oncogenes include erh-B，fms, and 
kit- These proteins span the cell membrane and possess an intracellular 
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cytoplasmic domain and an extracellular domain. Binding to these growth 
factor receptors extracellular domain ligands generally lead to the activation 
of the intrinsic tyrosine kinase activity of the intracellular cytoplasmic 
domain of the receptor molecule, which subsequently results in the 
induction of cell proliferation. 
The last class of proto-oncogenes locate in the nucleus. They 
fimction in the nucleus of the cell and regulate gene expression by 
interacting with other proteins and/or specific segment of DNA. This class 
of proto-oncogenes includes the myc group (c-myc, N-myc, and L-myc), 
—b, fos ets-\ , ets-2 and ski. Some of these genes have been demonstrated 
to encode nuclear proteins that bind regulatory regions in DNA, which 
subsequently regulate transcription of cellular genes. Gene products of 
these proto-oncogenes are also considered to play major roles in the 
transition from quiescence to proliferation in the cell cycle. In normal 
condition, nuclear proto-oncogenes help to regulate cell proliferation and 
differentiation. When they are mutated or inappropriately expressed, cell 
division and proliferation become uncontrollable and tumourogenic 
phenotype (Gompel et al, 1994). 
(2) Activation of proto-oncogenes 
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Oncogenes may be activated in a number of ways. The mechanisms 
are numerous. In some situation, point mutation may alter the protein 
encoded for by the gene (e.g. ras genes) but in some cases the protein is 
normal but it appears at a wrong times of the cell cycle. These alterations 
may be due to gene amplification, rearrangement and mutation or 
overexpression. Changes resulting in alteration of proto-oncogene to 
transforming oncogene could occur at DNA, RNA or protein level. 
Activation of proto-oncogenes can be induced by four mechanisms: 
insertional mutagenesis, gene mutation, chromosomal translocation, gene 
amplification. 
(a) Insertional mutagenesis 
Retroviruses are converted to double-stranded DNA copies of the 
RNA genome shortly after infecting a cell. These DNA copies are inserted 
randomly into the chromosomes. The effect of this random insertion or 
integration may be the placement of proviral regulatory sequences near 
cellular genes resulting in alteration of the expression of those genes. 
(b) Gene mutation 
33 
A gene is a linear array of bases dictating the amino acid content of 
a protein. Mutation in one or more of the bases might result in an altered 
protein. This may result in the inability of that protein to perform its normal 
function to regulate cell growth and differentiation. 
(c) Chromosomal translocation 
Chromosomal translocation activates the proto-oncogenes. It may 
be result from the evacuation of the proto-oncogene from normal control 
elements that regulate its function. Chromosomal translocations have been 
observed in a variety of human tumours (Nowell and Croce, 1988). This 
correlation was first noted for the c-myc oncogene, which located in human 
chromosome 8 and is translocated to chromosome 14 in Burkitts lymphoma 
cell (Dalla-Favera et al., 1982). 
(d) Gene Amplification 
Proto-oncogene can transform cells when excessive protein 
products is present. Many tumor cells contain amplified proto-oncogenes. 
They are usually located within expanded chromosomal regions. So called 
double minutes or homogenously staining regions on chromosomes. 
Amplified proto-oncogene expression may be related to development of a 
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more aggressive phenotype such as in certain lung tumours. For example, 
small-cell carcinoma of the lung may have 20-75 folds increase in myc DNA 
when compare to normal lung cells. Southern blot analysis is a method that 
can detect gene amplification. Amplified DNA is detected by increased 
signal intensity for the DNA in the cells of the amplified gene (Little et al, 
1983). Strong evidences support that the presence of one or more amplified 
oncogenes in tumors may be an important prognostic factor (Johnson et al., 
1986). High levels of amplification of N-wyc，YiEK-Hneu ,and c-myc have 
already been shown to correlated with poor prognosis of patients with 
neuroblastoma, breast cancer and small cell lung cancer (Johnson et al., 
1986). 
3.2.4.7 Oncogene and cervical cancer 
Invasive carcinoma of the uterine cervix is the second most frequent 
cancer in women worldwide. The biological behavior of cervical cancer is 
complicated by the possible involvement of human papillomavirus (HPV) in 
carcinogenesis (Liang et al., 1993). 
At this point, no definitive correlation has been established between 
abnormalities of cellular oncogenes and the biological behavior or clinical 
outcome of cervical cancer. However, considerable evidence suggests that 
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activation of cellular oncogenes is involved in the pathogenesis or 
development of cervical cancer (Riou, 1988). Report suggested that certain 
proto-oncogenes were involved in the development (Berchuck et al, 1990) 
and progression (Holm et al., 1993) of uterine cervical cancers. 
(1) c-myc and cervical cancer 
Most studies focused on c-myc. The data from both gene 
amplification and the oncoprotein overexpression were inconsistent, but it 
appeared that activation of c-myc occured in advanced stages of carcinoma 
which also suggested its possible role in tumour progression (Riou et al., 
1987，1990). Bqurhis et al. (1990) recently reported that overexpression of 
c-m少c was a strong and independent indicator of the risk of overall relapse 
and distant metastases, even in early-stage carcinoma (Bourhis et al., 1990). 
However, Symonds et al. (1992) reported that no correlation was found 
between c-myc overexpression and cervical cancer. 
(2) c-erbB2 and cervical cancer 
The c-erbB2 proto-oncogene encodes a growth factor receptor-like 
molecule with tyrosine kinase activity and has a structure similar to that of 
the epidermal growth factor receptor (Shechter et al., 1985; Akiyama et al., 
1986; Yamamoto et al., 1986). Results of c,-erbB2 overexpression in most 
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studies of uterine cervical squamous carcinoma were consistent with the 
overall low frequency of c-erbBl abnormalitties (Bmmm et al., 1992). 
However, Berchuck et al. (1990) used frozen rather than formalin fixed 
tissue and they found that all 26 cervical squamous cell carcinoma 
specimens were overexpressed with the c-erhBl onco-protein. In addition, 
a report also suggested that overexpression of c-erbm protein was 
associated with poor prognosis in cervical cancer (Kihana et al., 1994). 
(3) c-fos and cervical cancer 
Overexpression of c-fos oncoprotein has been reported in human 
osteosarcomas (Wu et al., 1990)，hepatocarcinoma (Arbuthnot et al., 
1991), colorectal adenomas and carcinoma (Magrisso et al., 1993)，lung 
cancer (Volm, Drings and Wodrich, 1993; Volm，EfFerth and Mattern, 
1992) and breast carcinoma (Walker et al., 1991). c-fos overexpression was 
also found to occur in cervical cancer (Petrov et al., 1994). However, the 
association of c-fos oncoprotein in the development of cervical cancer has 
not previously been extensively investigated. 
(4) p53 and cervical cancer 
The p53 gene is a tumour suppressor gene. It encodes a 53 
kilodalton nuclear phosphoprotein and locates on the short arm of 
chromosome 17 (Finlay et al., 1989; Diller et al., 1990). p53 plays a role in 
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the prevention of genomic instability (Lamb and Crawford, 1986). DNA 
damage will result in the increase ofp53 protein which blocks along the cell 
cycle in the Gl/S phase checkpoint and finally results in DNA repair or 
apoptosis (Yonish-Rouach et al., 1991). Alteration of the p53 gene may 
result in lost of tumour suppresser function of the gene and unlimited cell 
proliferation. Holm et al. (1993) indicated that the p53 overexpression may 
be involved in the progression of cervical cancer. 
Cervical cancer is known to be an important gynecological cancer. 
However, there is no specific tumour marker for early detection, accurate 
prediction of biological behavior and for accurate assessment of prognosis. 
Further investigations are needed to clarify which proto-oncogene play 
roles in the pathogenesis and development of this tumour as well as the 
potential diagnostic and prognostic value of oncogenes and tumour 
suppressor genes. 
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2.3 Immunohistochemical technique in cancer study 
2.3.1 Principle of immunostaining 
Immunostaining is a technique for identifying cellular or tissue 
constituents (antigens) by antigen-antibody reactions which can be made 
microscopically visible through the incorporation of a suitable label. 
In 1966，Nakane, Pierce and Uriel used enzyme peroxidase linked 
with a secondary antibody. The peroxidase can be visualized by developing 
under different substrates to produce brown, blue or yellow reaction 
product in light microscopy. The immunostaning procedure needs not work 
in the dark. In addition, the precise evaluation of morphology is easier and 
the preservation of the colour of the immuno stained slide is longer than 
immunofluorescent technique. So the immunoenzyme technique is used 
most commonly for diagnostic and research purposes. 
Immunocytochemical techniques can be used to study oncogenes 
expression in protein level. Many oncoproteins antibodies are commercial 
available now. The methods are now well established and become an 
essential part of diagnostic surgical pathology (Filipe and Lake, 1990). 
More recently, Immunohistochemical methods are focusing toward the 
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identification of prognostic markers of potential value in predicting the 
behavior or response to therapy of specific types of tumors. For example, 
K67 has demonstrated to be significant associated with early recurrence of 
cervical cancer (Chung et al., 1994). The Oncogenes research is now a 
popular subject (Baserga et al., 1993) and many papers focusing on it are 
published each years (Cattoretti et al., 1988; Stretch et al., 1991; Porter et 
al., 1992; Seruca et al., 1992). 
2.3.2. Fixation 
To ensure preservation of tissue architecture, cell morphology and 
antigenisity, fixation of fresh tissue with a suitable fixative as fast as 
possible after the resection of the tissue is the most important part before 
immunstaining (Fox et al., 1985). In routine practice, there is no single 
fixative that is ideal for the preservation of all antigens. Histopathologists 
usually use formalin-fixed paraffin sections which are often far from ideal 
for immunocytohemistry (Fox et al., 1985). The antigenic sites of some 
substances are masked or destroyed by routine formalin fixation. 
Fortunately, many diagnostically useful antibodies that do react with 
formalin-fixed paraffin-embeded material and most of the masked-antigen 
can be re-exposed through antigen retrieval method. For fresh-frozen 
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cryostat sections, fixing in methanol, acetone, or acetone mixed with 
chloroform is usually satisfactory for the preservation of antigens. 
2.3.3 Section preparation 
Sections for immunostaining could be picked up on slides coated 
with high molecular weight adhesive such as poly-L-lysine when protease 
or microwave treatment is used. Paraffin sections were dried at 37°C 
overnight in the oven and cryostat sections should be air-dried at room 
temperature for several hours or overnight before immunostaining studies. 
Many antigens which are masked or destroyed by paraffin or resin 
embedding, can be detected in cryostat sections. The advantages of the use 
of paraffin section rather than cryostat section in immunstaining are the 
good morphology and no fresh tissue is required. 
2.3.4 The choice of antibodies 
Antibodies is a class of serum proteins known as immunoglobulins. 
They are produced by plasma cells of the immune system, usually the end 
cell of B lymphocyte. Transformation after recognition of a foreign antigen. 
There are five types of antibody including IgA, IgD, IgE, IgG and IgM. 
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IgG is the commonest and most frequently used antibody for 
immunocytochemistry (Filipe & Lake, 1990). 
The advantage of monoclonal antibodies is that they are consistent 
and the same clone remains available and that they are of a single known 
immunglobulin subclass and have a defined specificity to one epitope of the 
antigen molecule. Comparing with the polyclonal antibodies, the 
disadvantage is that the particular epitope may not withstand formalin 
fixation and paraffin embedding. If the antibody is wrongly treated the 
entire antibody may be destroyed. 
2.3.2.5 Enzyme Labels 
Horseradish peroxidase is the most widely used enzyme label. 
Alkaline phosphatase and glucose oxidase also have their particular 
applications. An enzyme label must produce a coloured end product in the 
final step of the immunostaining procedure. The most useful reaction 
product is that derived from the oxidative polymerization of 3，3-
diaminobenzidine (DAB) (Hsu & Soban, 1982). The action of antibody-
bound peroxidase on hydrogen peroxide supplies the oxidizing power and 
the end-product deposited on the site of the antigen-antibody reaction is 
dark brown and insoluble. A light haematoxylin counterstain usually 
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provides enough background staining and the slides can be dehydrated in 
graded alcohol, clear in xylene and mounted in a permanent mountant. 
2.3.6 Blocking endogenous enzymes 
In some normal and neoplastic tissues, e.g. leukocytes and 
erythrocytes, peroxidase and substances can give a pseudoperoxidase 
reaction and lead to difficult in interpretation of the result. Various methods 
can destruct the activity of pseudoperoxidase reaction. The most 
frequently used method is pre-incubation of the sections in tris-buffer 
containing 0.3% hydrogen peroxide. Usually, blocking for 10-20 minutes at 
room temperature will be enough. 
2.3.2.7 Blocking background staining 
Specific background staining e.g. fibrinogen in blood vessels and 
immunglobulins in serum-bearing tissues and nonspecific background 
staining due to inflammatory exudate or necrosis or delayed fixation may 
give rise to false positive results and misinterpretation. It can be avoided by 
using an anti-albumin control to identify the affected cells. Furthermore, the 
use of high dilution of primary antibody in Avidin-Biotin Complex (ABC) 
method (Hsu, Raine & Fanger，1981) or peroxidase anti-peroxidase (PAP) 
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method and other sensitive methods will greatly reduce the non-specific 
background staining. In addition, it can also be reduced by the use of a high 
salt concentration (2.5% NaCl). 
2.3.2.8 Dilution of antibodies 
It is important that the primary specific antibody is used in optimal 
dilution in order to obtain the best staining pattern (high sensitivity and 
minimal or no background staining). Incorrect dilution can give rise to false 
negative results as well as strong background staining (Bigbee et al., 1977). 
2.3.2.9 The Avidin-Biotin Complex 
Avidin is a basic glycoprotein (mol. wt. 68kda ) which has a high 
affinity for the small water-soluble vitamin biotin. Biotin can be conjugated 
to a variety of biological molecules including antibodies. In the Avidin-
Biotin Complex (ABC) method (Hsu, Raine & Fanger，1981) (Figure 2.3) a 
complex of avidin and biotinylated tracer, which contains free biotin binding 
sites, is applied to the biotinylated antibody. The techniques use the high 
number of biotin-linked peroxidase molecules attached to a single antibody. 
This gives high sensitivity and allows a high dilution of the primary 
antiserum to be used. The advantage of the method is that any species can 
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be used to provide the biotinylated second layer and the third layer is 
universal and not dependent on the species of the primary antibody. The 
avidin-biotin complex (ABC) methods are even more sensitive than the 
peroxidase anti-peroxidase (PAP) method because of the large amount of 
label that can be built up at the site reaction (Hsu, Raine & Fanger, 1981; 
Sternberger et al., 1986). 
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Figure 2.3 Staining sequence in the Avidin-Biotin-Peroxidase Complex 
(ABC) method (Hsu, Raine & Fanger, 1981). 
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2.3.2.10 Controls 
A positive control in each batch of staining is necessary for many 
steps which must be in the correct and optimal condition. However, a 
negative result in the presence of a positive control does not always means 
that the antigen is totally lacking. It may be that the quantity present is too 
small to be picked up by the method used or that epitope(s) recognized by 
the antibody have been destroyed or hidden by the processing of the tissue. 
A negative control should also be added on each staining using normal 
serum or buffer substitute for the primary antibody. This can allow the 
investigator to access the level of background staining. 
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2.3.2.11 Antigen retrieval 
In formalin-fixed parafFin-embeded tissue, antigen sites may be 
masked or destroyed (Finley and Petrusz, 1982). Therefore, two antigen 
retrieval methods are usually used for re-expose antigens and increase 
sensitivity of immunocytochemistry method. 
(1) Enzymatic pre-treatment 
The enzymatic pre-treatment method not only can enhance 
immunocytochemical staining but also to improve the reliability and 
sensitivity of immunocytochemical methods (Snead et al., 1993). However, 
It is difficult to find the most suitable condition. Low concentration and/ or 
short time treatment were inadequate to unmask antigens while prolonged 
exposure to the enzyme may reduce the immunostaining and result in bad 
morphology because of overdigestion. The recommended enzymes for 
section digestion are trypsin, pepsin, and various proteases such as pronase 
(Snead et al., 1993). 
(2) Microwave irradiation antigen retrieval 
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Recently, an alternative method instead of enzymatic pre-treatment 
using microwave radiation of tissue sections in a lead thiocyanate-
containing solution has been shown to improve immunostaining of 
sensitivity of overfixed tissue sections in a group of antigens than with 
enzymatic pre-treatment (Momose et al, 1993). However, the boiling of 
toxic lead-containing solutions in microwave oven may be against the 
laboratory safety. Other microwave retrieval solution were studied 
including citrate, urea, glycine HCl, sodium carbonate. Some antigens are 
selectively "unmasked “ with the retrieval solution of citrate or carbonate 
ions，some are apparently best retrieved with a protein denaturant such as 
urea (Cattoretti et al., 1993). 
Other antigen retrieval method such as the use of autoclave or 
pressure cooker preheating of sections in an aqueous salt solution was also 
reported to have the same effect of increasing immunoreactivity (Shin et al., 
1991; Navabi et al., 1994). The actually mechanism of this high-
temperature antigen enhancement is still being investigated. 
2.3.2.12 Cell counting and scoring 
Although immunohistochemical staining has been widely used in 
clinical and pathological research, few reports have been devoted to 
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describe the counting methods. In addition, the cell counting methods and 
scoring methods are inconsistent. There were various quantitative counting 
methods reported in the literature by counting cell based on representative 
area under high power field. Other methods based on the total number of 
cell counted. In addition, some authors count cells with the help of 
photograph and manual image processor or analysis system. Moreover, 
computerized image analysis systems for cell counting are available 
recently. Semi-quantitative cell-counting methods are the methods most 
commonly used in studying oncoprotein expression by 
immunohistochemistry. Usually, 500-3000 cells is count (Bai et al, 1994). 
Some authors used semi-quantitative methods to divide the percentages of 
positively stained cell in to three to five grades (David et al., 1993; 
Magrisso et al., 1993; Xu et al., 1994; Ng et al., 1994). Some related 
grading methods are list in table 3.2.2. 
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Table 3.2.2 Various grading or counting methods reported in the 
literature. 
Antibody Grading Author 
P53 Expression was evaluated on the uniformity and intensity of Magrisso et al., 1993 
staining as follow: ’ 
1. Uniform, >50% of the cells/section stained, scattered 
<50% stained. 
2. Intensity : (0) negative, (+-) equivocal stain,(l+), light but 
positive staining, (2+), moderate to strong staining 
P53 1 . 0 % no nuclear staining Xu et al 1994 
2. 10-30% + •， 
3. 40-70% ++ 
4. >70% +++ 
P53 1.1-25% + Ngetal. , 1994 
2.26-50% ++ 
3. >50% +++ 
P53 l . (N) negative Bur et al.，1991 
2. (W/F) weak/focal 
3. (S/D) strong/ diffijse 
1 .Faint intensity + Singleton etal., 1994 
2. moderate to strong intensity ++ 
3. Strong intensity +++ 
c-e/"fcB2 1. Positive membrane staining of increasing intensity as 1 +, Berchuck etal 1990 
2+, 3+ . ‘ .’ 
c-erfcB2 1. (+) weak positive (the cytoplasmic of at least half of the kihama et al.，1994 
cells was weakly and definitely stained) ， 
2. (++) strongly positive (the cell membrane was definitely 
stained in all or a substantial portion of the cancer cell. 
c -础 B2 l .weak (1) Lipponen, 1995 
2. moderate (2) 
.3. intense (3) 
c-w少c The proportion of stained cells was determined by counting Bai et al 1994 
1,500 epithelial cells. .， 
negative Volm et al.,1992 
2. positive 
c - 亭 1. five high power random field of average positive rate of Lipponen, 1995 
nuclear staining 
2. cytoplasmic staining was scored into four categories as 
negative, weak, moderate and strong 
c /ay 1 • Negative Volm etal., 1992 
2. Positive 
c-/o.y Expression was evaluated on the uniformity and intensity of Magrisso et al., 1993 
staining as follow: 
1. Uniform, >50% of the cells/section stained, scattered, 
<50% stained. 
2. Intensity: (0) negative, (+-) equivocal stain,(l+), light but 
positive staining, (2+), moderate to strong staining 
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2.4 The application of PCR-SSCP in cancer research 
In the past few years, there were increasing evidences that a large 
variety of human tumors contain changes of genetic component. A large 
volume of DNA sequence data is available. Detection of sequence changes 
in individuals or cell line is possible linkage analyses of genetic 
polymorphisms, detection for mutations of particular sequences in cell 
clones, large insertions or deletion or the nucleotide substitutions that 
happen to disrupt or create recognition sequences of restriction enzymes 
can be detected by Southern blotting after digestion with the appropriate 
enzymes (Restriction fragment length polymorphism, RFLP)(Bostein etal.， 
1980). The disadvantage of Southern blot analysis is that a relatively large 
quantity of tissue is needed in order to isolate sufficient quantity of genomic 
DNA for analysis. A new method have reported by Orita et al. (1989) that 
detects sequence changes with single-strand shifts in electrophoretic 
mobility. The polymerase chain reaction (PGR) was first introduce in 1985. 
It soon becomes a important technique in clinical and molecular research 
laboratories (Erlich et al., 1991). PGR DNA amplification is the most 
sensitive method for nucleic acid detection currently available. Although the 
amount of target DNA present in the sample is very little, a large numbers 
of the target molecule can be synthesized though PGR reaction. DNA 
polymerases will copy a specific single-stranded DNA after primers are 
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added and bound at the specific region of DNA and amplified in a optimal 
time and temperature in the PGR reaction. 
Primers are the short segments of DNA (oligonucleotides) which 
act as initiation points of DNA amplification in PGR reaction. The PGR 
reaction is based on repeated cycles of heat denaturing, annealing and 
extension. In heat denaturing procedure, the target DNA is heated at 
around 94 °C for about 1 minute. This allows the hybridization (annealing) 
of primer to the target at 5 5 � C Taq DNA polymerase then extends the 
primers with other essential reagents including a PGR buffer and the 
four nucleotide building blocks dATP，dCTP, dGTP, and dTTP, which will 
be collectively referred to as dNTPs at around 7 2 � C . Choosing the primers 
so that each will be complementary to a region of the DNA molecule 
toward the 3，end of the two DNA target stands. When the temperature is 
raised to 94 °C again, the new strands separate from the template DNA 
when the temperature is decreased to 55 °C, the annealing temperature, 
each of the primers may anneal to their complementary base pair sequences 
on the two newly synthesized strands respectively. 
Successive denaturation annealing and extension will lead to the 
repeated synthesis of the DNA sequence. PGR allows production of large 
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quantities of specific DNA sequences in a single tube within a few hours. 
DNA polymerases require a small section of double-standed DNA to 
initiate or "prime" synthesis of the new strand. The net result of PGR is that 
at the end of n cycles, the reaction tube will contain a theoretical maximum 
of 2" double-standed molecules representing copies of the sequence 
specified by the two primer between the two primers. PCR-SSCP is a 
method using the target sequences to be examined are amplified and labeled 
by the polymerase chain reaction (Saiki et al., 1988). Using labeled primers 
or a labeled nucleotide, followed by denaturation and electrophoresis for 
SSCP analysis (PCR-SSCP analysis). It is a fast method in screening 
mobilities shift of genetic structure, possible mutation or deletion. It relies 
on the different sequences of single-standed DNA or RNA strands exhibit 
different mobilities during electrophoresis in non-denaturing polyacrylamide 
gels. Under non-denaturing conditions, single-standed DNA exhibits a 
folded structure which is stabilized by intrastrant interactions force. In this 
technique, sample DNA is digested with a restriction enzyme, heat 
denatured and running in polyacrylamide gel electrophoresis under 
nondenaturing conditions. The target sequence is then detected after 
electroblotting and hybridization to a probe. The detection of a mutated 
sequence is determined by the changed mobility in the polyacrylamide gel 
electrophoresis. 
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Only a single point mutation within a sequence will lead to a change 
of running behavior in which can be detected by this method. The 
occurrence of mutational changes in the DNA sequence will cause a 
changed of the normally folded structure. Lenghth of sequence of the PGR 
fragment are the main factor influencing the sensitivity of the method. 
Sarkar and co-workers had shown in a systematic study that under 
optimized condition, 92% of all mutation would be detected by this 
method. When the length of sequence up to 307 bp, the detection rate 
decrease into 59% of all mutation (Sarkar et al., 1992). 
Too much heat generated during electrophoresis will also alter the 
running behavior of the samples. So, it is better to use a water-jacketed 
electrophoretic apparatus or run gel under 5-7 °C condition. In addition, 
thin gels may decrease the heat generated during electrophoresis. Adding 
5% ofN,N'-methylene bisacrylamide and 5-10% glycerol may also increase 
the sensitivity of the method. However, the results of SSCP gel may be 
difficult to interpreted. Recently, Denenbery and co-worker had established 




Materials and Methods 
3.1 Materials 
(a) For immunohistochemistry 
Serum Buffers 
1. 5% Normal rabbit serum in 0.05M TBS pH 7.6 (Dako) 
2. 5% Normal swine serum in 0.05M TBS pH 7.6 (Dako) 
3. 5% Normal horse serum in 0.05M TBS pH 7.6 (Dako) 
Blocking Reagent 
1. 0.3% H2O2 in 0.05M TBS (pH 7.6) 
2. 5% bovine serum albumin (BSA) (Dako) 
Tris Buffer Saline (TRS) 
Stock solution 4L: 
Tris 242gm (Sigma) 
NaCl 360 gm (Merk) 
Cone. HCl 130 ml (Merk) 
Add double distilled water (啦。）to 4L 
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Adjust pH to 7.6 
Working solution : 
TBS stock solution 200 ml 
Add distilled water to 2000 ml 
Filter before use 
Retrieval buffers 
1. For p53，c-e!他2’ c-fos : 
Citric acid 2.1g/L(Sigma) 
Adjust pH to 6 
2. For c-myc: 
4 M urea (BDH) 
Primary antibodies-
1. Human c-myc [171-188] monoclonal antibody clone 6E10 
(Cambridge Research Biochemicals) 
2. Human c-erbm [1238-1255] monoclonal antibody (Cambridge 
Research Biochemicals) 
3. HCS 20ES: p53 Immunohistochemistry Kit (Ab-6, Oncogene 
Science). 
4. z-fos (Ab-2) polyclonal antibody (Oncogene Scinece) 
Secondary antibodies 
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1 • Biotinated swine anti-rabbit immunoglobin (Dako) 
2. Biotinated horse anti-abbit immunoglobin (Oncogene Science) 
3. Biotinated rabbit antimouse immunoglobin (Dako) 
Avidin-Biotin peroxidase complex rARC mmplpv) (Dako ABC Kit) 
Avidin solution 10 |Lil/mI in TBS, pH 7.6 
Biotinylated peroxidase solution 10|al/ml in TBS, pH 7.6 
Mix thoroughly and prepare the mixture 30 minutes before use 
DAB Solution 
Stock solution: 
3，3:-Diaminobenzidine Tetrahydrochloride 1.25gm (Sigma) 
Add 0.05 M TBS pH 7.6 to 50 ml 
Aliquots to 1ml/ tube and store at -20 °C 
Working Solution: 
Stock solution 1ml 
Add 0.05M TBS pH 7.6 to 49 ml 
Add 30 % H2O2 50 |Lil 
(2) Materials for PCR-SSCP 
Digestion buffer: 




20|Lig/ml proteinase K 
0.5% SDS (Sodium dodecyl sulfate) 
Add H2O to 100ml 







(The primers were kindly provided by Prof. PG Rothberg, 
University of Missouri, Kansas City, School of Medicine, USA) 
I P X PGR buffer 
lOOmM Tris-HCl, pH 8.3，500mM KCl ,25mM MgCh 
IPX dNTPs (Phamacia) 
2mM each of dATP, dCTP, dTTP, and dGTP 
Tag polymerase (Boehringer Mannheim) 
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Sequencing stop solution 
lOmMEDTA (Sigma) 
0.0Ig bromphenol blue (Sigma) 
0.0Ig xylene cyanol (Sigma) 
0.5ml dHzO 
Add Formamide (pH 8) to 10ml 
TBE electrophoresis buffer 
lOX stock solution 1 L 
108g Tris-base (Sigma) 
55g boric acid (Sigma) 
40ml 0.5 M EDTA pH 8.0 (Sigma) 
Add dH20 to IL 
6% Acrylamide gel 
40% Acrylamide-Bisacrylamide gel (29:1 ) 12ml (Sigma) 
1 OX TBE 4ml 
H2O 64ml 
10% APS (Ammonium persulfate ) 0.08g (Sigma) 
TEMED (NNN'N'-tetramethyllenediamine) 50 |li1 (Sigma) 
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X-ray film (Kodak, Rochester, NY) 
3.2 Methods 
3.2.1 Specimen collection 
� Tissue for immunohistochemical staining 
A total of 95 cervical samples were studied. 24 were collected from 
the files of the Department of Anatomic and Cellular Pathology, CUHK 
，Prince of Wales Hospital from 1986-1992. 71 samples were collected from 
the Department of Obstetric and Gynaecology, CUHK, PWH from 1993-
1995. 30 case were CIN, 8 cases of them were CIN 1, 9 cases were CIN 2 
and 13 cases were CIN 3; 57 cases were cervical carcinoma, 38 of them 
were squasmous cell carcinoma, 15 were adenocarcinoma of cervix, 3 
adenosquamous carcinoma and one small cell carcinoma. In addition, 8 
cervical biopsy specimens collected from women undergoing minor 
gynaecological procedures for benign diseases were included as controls. 
The specimens selected for the study should fulfill the following 
criteria. (1) All specimens were collected at surgical operation or biopsy 
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under colposcopy. (2) All the specimens did not receive any radiotherapy or 
chemotherapy before the specimen collection. (3) All specimens should be 
fixed in 10% buffer-formalin within 15 minutes after resection. 
Four-micrometer sections were cut, mounted on poly-L-lysine-
coated slides and heated in an oven at 4 5 � C overnight to promote 
adherence of the tissue to the slide. 
One of the sections of the each tissues were mounted on slides and 
stained with haematoxylin and eosin for histopathologic diagnosis. 
(2) Fresh tissue for DNA extraction 
Fresh tissues of 30 cases of cervical cancer were collected for DNA 
extraction. The percentage of the tumor cells in the specimens was 
confirmed histologically in all the cervical carcinomas to be more than 50%. 
(3) Blood 
20 ml of peripheral blood was collected into a tube containing 2.5ml 
of sodium citrate for DNA extraction. 
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3.2.2 Antibody preparation 
The antibodies used in this study were listed in the section of 
materiel. Each antibody was titrated in a serial of dilution to obtain their 
optimal dilution on the appropriate paraffin sections. 
Formalin as a fixative may destroy or "mask" some epitopes by 
cross-linking proteins or other unknown mechanisms. A study comparing 
enzymatic unmasking (pronase, trypsin) and non-enzymatic unmasking 
(microwave antigen retrieval) was carried out. Furthermore, a study was 
carried out to compare different antigen retrieval buffers including citric, 
glycine，urea and normal saline for each antibody. 
3.2.3 Antigen retrieval and immunohistochemical staining procedures 
Antigen retrieval procedure 
(1) For detection of c-erbB2 and c-fos oncoprotein 
1. DeparafFinized and rehydrated tissue sections. 
2. Placed slides in a plastic container filled with sufficient 
citric-buffer for tissue to retain hydration during subsequent 
heating. 
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3. Covered but did not seal the container. Be sure the container 
was ventilated to allow for the release of pressure. 
4. Put container with slides in an open plastic tray containing 5 
cm of water to catch boil-over, and placed in a microwave 
oven (GM 10IT，GMT, Korea). 
5. Microwaved at high power for 5 min. 
6. Checked amount of citric-buffer solution in container and 
added dHzO. if necessary, to prevent slides from drying out. 
7. Microwaved for an additional 10 min on medium power. 
8. Removed container from oven and allow to cool for 15 min 
in running water. 
9. Washed slides once in dHsO, then place in TBS, pH 7.6. 
Slides were ready for immunostaining. 
(2) For detection of c-myc protein 
Place slides in a plastic container filled with sufficient 4M urea in 
step 2. Other procedures were same as above. 
(3) For detection of p53 protein 
Microwaved for a total of 15 min on medium power in step 7. Other 
procedures were same as above. 
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Immunohistochemical staining 
(1) Immunostaining for c-erbB2 
1. Washed slides in TBS, pH 7.6 after microwave pretrement. 
2. Blocked endogenous peroxidase activity in blocking reagent for 20 
min. 
3. Transferred slides to tap water and rinsed slides briefly with TBS, 
pH 7.6. 
4. Incubated section in serum buffer for 10 min. 
5. Drained sections but did not wash sections. 
6. Incubated section with primary antibody c-erbB2 (1:1000) for 16 
hours. 
7. Washed in TBS, pH 7.6 and changed buffer 3 times in 10 min. 
8. Incubated sections with secondary antibody (biotinated rabbit anti-
mouse immunoglobulins 1: 200) for 30 min. 
9. Washed in TBS, pH 7.6 and changed buffer 3 times in 10 min. 
10. Incubated in ABC complex (1:100) for 45 min. 
11. Washed in TBS, pH 7.6 and changed buffer 3 times in 10 min. 
12. Developed in DAB solution for 5 min and checked color under 
microscopy. 
13. Washed in tap water for 20 min. 
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14. Counterstained nuclei with Harris haematoxylin and differentiated 
and blued in Scot tap. 
15. Dehydrated in a 37 °C oven 
16. Cleared in xylene and mounted with premont. 
(2) Immunostaining for c-myc protein 
1 • Washed slides in TBS after microwave pretreatment. 
2. Blocked endogenous peroxidase activity in blocking reagent for 20 
min. 
3. Transferred slides to tap water and rinsed slides briefly with TBS. 
4. Incubated sections in 5% normal rabbit serum for 10 min. 
5. Drained sections but not wash section. 
6. Incubated section with primary antibody c-myc (1:400) for 16 
hours. 
7. Washed in TBS and changed buffer 3 times in 10 min. 
8. Incubated sections with secondary antibody (biotinated rabbit anti-
mouse 1:200) for 30 min and then went to as step 8 in the 
procedure of immunostaining ofc-erhB2 protein. 
(3) Immunostaining for p53 protein 
1 • Washed slides in TBS after microwave pretrement. 
2. Blocked endogenous peroxidase activity in blocking reagent for 20 
min. 
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3. Transferred slides to tap water and rinsed slides briefly with TBS. 
4. Incubated sections in 5% normal house serum. 
5. Drained sections but did not wash section. 
6. Incubated sections with primary antibody (p53 1 ： 25) for 16 hours. 
7. washed in TBS, changes buffer 3 times in 10 min. 
8. Incubated sections with secondary antibody (biotinated house anti-
human immunoglobulins 1: 200) for 30 min and then went to step 9 
in the procedure of immunostaining ofc-erbBl protein. 
(4) Immunostaining for c-fos protein 
1. Washed slides in TBS after microwave pretreatment. 
2. Blocked endogenous peroxidase activity in blocking reagent for 20 
min. 
3. Transferred slides to tap water and rinsed slides briefly with TBS. 
4. Incubated sections in 5% normal swine serum for 10 min. 
5. Drained sections but did not wash section. 
6. Incubated section with bovine serum for 10 min and drained 
section. 
7. Incubated section with primary antibody c-fos (1： 25) for 16 hours. 
8. Washed in TBS, changed buffer 3 times in 10 min. 
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9. Incubate sections with secondary antibody (biotinated swine anti-
rabbit immunoglobins 1: 200) for 30 min and then went to step 9 
as the procedure of immunstaining of c-erbE2. 
Positive and negative controls were included with each 
immunostaining. As positive controls of p53 oncoprotein, breast cancer 
sections provided by the Oncogene Science company with the staining kit 
were enclosed. For c-myc oncoprotein, positive control slides of 
Nasophangeal carcinoma were offered by Mr. David Lo. For c-erbB2 
oncoprotein detection, breast cancer sections were added. In negative 
control slide, the primary antibody was omitted. 
3.2.4 Cell counting and scoring 
The cell counting and immunoreactivity scoring in this study were 
according to the following criteria. 
(1) For c-erbB2 oncoprotein, staining intensity was assessed by 
evaluating the overall staining in each entire section comparing with the 
positive control sections with a semiquantitation scale ranging from no 
expression (-) to weak expression (+), moderate expression (++) and 
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strong expression (+++). Peripheral area of sections, necrotic areas and 
background staining were disregarded. 
(2) The fractions of nuclei positive for p53, c-myc and c-fos 
protein were scored in the entire section by using an objective magnification 
of X 400. Positive number of cells were accessed by 10 high-power view 
though microscope randomly chosen. The total number of positively stained 
tumour cells in each field (F) were added together and divided by the total 
number of tumour cell in these ten field (T) to get a percentage: 
(FRF2+F3+……F10)/(T1+T2+T3+.....TIO) X 100%. Furthermore, those 
nuclear staining was not reproducible or extremely weak were regarded as 
negative staining. Again, all edges of sections, necrotic area and 
background staining were not counted. All slides were examined with the 
H&E staining of the section in the same tumour tissue block. These 
antibodies were nuclear staining pattern and the immunostaining was 
estimated as the percentage of positively stained cell. The result was 
negative when there was no nuclear staining. The proportion of malignant 
cells staining was scored between 0 (-) to 3+, with (-) representing no 
nuclear staining, (+) with less than 25% of malignant cells staining, (++) 
with 25-50% positive cells, (+++) with greater than 50% positive cells (Ng 
et al, 1994). Scoring and assessment of the staining patterns were made 
without knowledge of the clinical or pathological data on each patient. 
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3.2.5 PCR-SSCP analysis of c-myc gene mutations 
Single-strand conformation polymorphism (SSCP) analysis is widely 
used to scan genes for single base differences. This method has been 
demonstrated to be effective in detecting polymorphism and identifying 
disease-causing mutations. The method typically involves the amplification 
by PGR of discreet segment of genomic DNA in the presence of 
radiolabeled nucleotides, melting of PGR products, and analysis of the 
single strands on non-denaturing polyacrylamide gel. 
3.2.5.1 DNA extraction from blood and tumour tissue 
Beginning with blood 
(1) Added Lysis Buffer to each 50 ml tube (1:10 dilution), then, 
inverted gently until lysis is complete (about 3 min). 
(2) Spined centrifuge 15 min at 3,200 rmp at 4 � C . 
(3) Decanted supernatant, then , resuspended pellet in about 4.5ml TE. 
Added 0.5 ml 10% SDS and 100 [i\ Proteinase K (20 mg/ml). Set in 
65 °C water bath until clear. 
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Beginning with tumour tissue 
(1) Removed the tissue from -70�C，then, minced the piece of tumour 
in a tube with TE. 
(2) Volumes for the digests could vary but a good starting point was 
170 III TNE, 20 10% SDS, \0[i\ Proteinase K (20 mg/ml). 
(3) Incubated the sample at 65°C until it became clear and the small 
pieces had digested. 
Extraction of nucleic acid 
(1) Added 5-10 ml phenol/chroroform/isomylalcohol (24/25/1), 
inverted gently to emulsify, and centrifliged at 2,800 rmp for 2 min 
at room temperature. 
(2) Aspirated top aqueous layer with pipette and transferee! to 2nd tube 
containing 5-10ml phenol/chloroform/isoamylalcohol (25/24/1), 
inverted gently to emulsify, and then centrifliged as in (1). 
(3) Transferee! aqueous layer to a fresh tube, added 15 ml of 
chloroform/isoamylalcohol (24:1), and mixed. Then centrifliged 
3,200 rmp 1 min. 
(4) Transferee! the aqueous (top) layer to a new tube and added 1/2 vol 
of 7.5 M ammonium acetate and 2 (original) volumes of 100% 
ethanol. Recovered DNA by centrifugation at 5,000 rmp for 2 min. 
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(5) Rinsed the pellet with 70% ethanol. Decanted ethanol and vacuum 
dried the pellet. 
(6) Resuspended the pellet with sterile distilled water until dissolve, and 
determined its concentration. 
3.2.5.2 PGR 
(1) Made a master mix containing all SSCP components except 
template DNA in the hood. In a sterile tube assembled and mixed 
the following components 
7.5 111 H2O 
1 \x\ lOX Taq DNA Polymerase Buffer* 
0.1 |Lil Sense primer (50 p m o _ * * 
0.1 |Lil Antisense primer (50 pmol/|al)** 
0.1 |Lil dNTP (2.5mM) 
0.5 |Lil Formamide 
0.1 [i\ Taq DNA polymerase (5 unit/pil) 
0 . 1 . 3 2 p - d C T P ( 1 0 | L i C _ 
Multiplied these volumes by the number of samples to be amplified 
for master mix. Include no DNA, negative and positive controls. 
*Regular lOX Taq DNA polymerase buffer from Promega Corporation, 
Madison, USA. ‘ 
** Three pairs of primers are used. 
1. Primers Myc X2A & B 
2. Primers Myc X2C & D 
3. Primers Myc X 2 E & F 
(2) Aliquoted 9.5 master mix into each numbered 0.5 microtube. 
(3) Added 0.5 |al genomic DNA (100 ng/|il) to the appropriate tube 
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using disposable-tip micropipettes. 
(4) Mixed the samples and centrifliged briefly. 
(5) Placed the samples in the thermal cycler (PTC-100 TM 
Programmable Thermal controller MJ Research, Inc.) and ran the 
appropriate file with the following conditions: 
94°C 5， 
94°C 45" and 72°C 50", and repeat it by 29 times 
72°C 8， ‘ 
Keep at 4°C 
3.2.5.3 Preparation of single strand DNA 
(1) 2[i\ of PGR reaction were diluted in 9 i^l sequencing stop solution, 
and then 2[i\ of 0.02 M NaOH were added, mix ed and centrifliged 
briefly. 
(2) The sample were heated for 10 min at 95°C and chilled on ice prior 
to electrophoresis. 
(3) Prepared one sample without heating denature to be as double 
strands DNA control, which contained 1 \x\ of loading buffer, 2 |li1 
of PGR reaction and 10 i^l of distilled water. 
3.2.5.4 Electrophoresis 
6% acrylamide-10% glycerol-0.5X TBE gel was used. 
A. Preparation of the glass using BRL Sequencing Systems (Life 
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Technologies, Inc) 
(1) Cleaned each plate by putting a piece of tape on one side. The taped 
sides of each plate should always be the back side, i.e., the side 
away from gel. 
(2) Siliconized the non-taped side of the long plate. Followed the 
instructions supplied with the siliconizing agent. 
(3) Laid the long gel plate on the lab bench or other flat surface with 
the gel side facing up (tape side down). 
(4) Placed a spacer along the length each of the outer edges of the 
glass. 
(5) Carefully laid the notched plate face down (tape side up) on top of 
the long plate. Aligned the plates, making sure the spacers are flush 
along the edges of the plates. 
(6) Used 3M gel casting tape to tape the long sides and bottom edges 
of the gel plate assembly. Applied light pressure as you pressed the 
tape in place. The bottom tape should be removed prior to 
electrophoresis. 
(7) Inserted the comb in the top of the taped plate set to check for a 
snug fit. If the comb appeared to fit too loosely, the top part of the 
plates should be retaped. Applied more pressure on taping the 
plates. 
(8) Removed comb before attempting to pour gel. 
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B. Preparation of SSCP gel 
(1) Assembled gel components in a 250 ml flask. 
To prepare a 6% acraylamide with 10% glycerol: 
40% acrylamide gel (29:1) 18 ml 
5XTBE 12 ml 
H2O 77 ml 
Glycerol 12 ml 





(2) Poured solution into gel mold using a 25 ml pipette, placed inverted 
sharks tooth comb (0.4 mm thick) deep to form a well. 
(3) Placed 5 clamps on the top and 3 each side of the gel. 
(4) Let the gels polymerize at least 1 hr at room temperature before 
sample loading. 
C. Gel system assemble 
(1) When the gel had polymerized (hardened), remove the tape from 
the bottom edge of the plate assembly. 
(2) Removed the extraneous acrylamide from around the comb with a 
razor blade. 
(3) Cleaned extraneous acrylamide from the plate surfaces. 
(4) Inserted the upper buffer chamber into slot on lower buffer stand. 
The drainage hose should be the rear of the unit. 
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(5) Gently placed the bottom of the plate assembly into the lower 
chamber. Be sure that the notched plate was away from you. 
(6) Attached the side clamps. 
(7) Filled the lower buffer reservoir with 0 .5XTBE until solution was 
approximately 10 mm above the bottom of the plates (about 800 
ml). 
(8) Filled the upper buffer chamber with 0.5 X TBE (about 1300 ml) 
until solution was approximately 10 mm above the bottom of the 
notch in notched plate. 
(9) Checked for leaks. 
D. Sample loading and electrophoresis 
(1) Carefully removed the comb from the gel and cleaned it. Reinserted 
the comb between the plates with teeth down. Inserted until the 
teeth barely indent the polymerized gel. 
(2) Rinsed the wells to remove any acrylamide. 
(3) Loaded 3 |li1 of each sample per well. 
(4) Closed the safety lid. Ran electrophoresis at 40 W for gels without 
glycerol about 4 hr and ran at 5 W for the gels with 10% glycerol 
about 16 hr in refrigerator respectively. 
3.2.5.5 Gel dry and scanning 
(1) Drained upper and lower chambers of electrophoresis apparatus. 
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(2) Undamped plates and removed tape from the plates. 
(3) Separated one plate from the gel using a large spatula. 
(4) Cut large piece of Whatman 3 mm to approximate gel size and laid 
on the gel by bowing it in the middle. 
(5) Peeled gel off other plate. 
(6) Covered gel with saran wrap and trimed edges of 
gelAVhatman/saran wrap to fit the gel dryer. 
(7) Cut second piece of Whatman 3 mm to gel size, placed on dryer and 
placed gelAVhatman/saran wrap on top of this. 
(8) Turned on vacuum and heat the gel at 80 °C for 45 min. 
(9) Exposed dried gel to Koda-X-ray film with two pieces of 
intensifying screen at -70°C for over night. 
3.2.6 Statistical analysis 
The association between oncogenes overexpression and clinico-
pathological parameters was statistically analyzed using Chi-square test 
(Magrisso et al., 1993) and Fisher's Exact test (Volm et al., 1992). 




Microwave antigen retrieval method increased both the number of 
immunoreactived cells and intensity in all four antibodies ( c-myc, c-fos, 
p53 and c-erbB2) compared with sections without pretreatment. No 
immunoreactivity was observed when there was no microwave 
pretreatment in detection of p53 protein (table 4.1). Trysin and pepsin 
pretreatment of section increased immunosensitivity ofc-erbB2, c-myc and 
c-/ay but it resulted in bad morphology of section and rendered scoring 
difficult. 
For microwave antigen-retrieval buffer, normal saline, citric-buffer， 
4M urea and glycine were tested. The optimal result was obtained by the 
use of citric-buffer in p53, c-fos and c-erbB2 staining while urea got a 
better staining for monoclonal antibody to c-myc (table 4.2). 
As for the duration for microwave antigen-retrieval, usually 10-15 
minutes boiling in a domestic microwave oven was found to be sufficient. 
There was no significant enhancement after 15 min of microwave 
pretreatment. Prolonged boiling in the oven would result in unleashed of 
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the sections. The expression patterns of the proto-oncogene protein c-
er办B2，c-myc, c-fos and tumour supressor gene p53 were shown in Figure 
1-22. 
In this study, c-erbm, c-fos, c-myc and p53 oncoproteins were 
detected using immunohistochemistry. The relationship between proto-
oncogene and tumour supressor gene proteins, and clinical and pathological 
parameters of cervical neoplasm were analyzed. The results obtained for the 
30 patients with CIN and 57 patients with cervical cancer were summarized 
in Table 4.3, 4.4, 4.5. The relationship between oncoprotein overexpression 
and International Federation of Gynecologists and Obstetricians staging 
(FIGO) of carcinoma of tumours, patient survival, age, pathological grade 
and recurrence of the disease was also accessed. 
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Table 4.6 a 
A comparison of results obtained by different antigen retrieval methods 
滅 b o d y ^ Pronase Trysin Microwave/ 
tested treatment citric-buffer 
_： _： - ^ ^ 
c-myc + + ~ ‘ 
c 如 + ++ "++ " T + + ~ ‘ 
c-erbB2 + 
- No staining 
+ no treatment or no change after treatment 
++ intensity slightly increased after treatment 
+++ intensity strongly increased after treatment 
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Table 4.6 a 
A comparison of the results obtained by different antigen retrieval buffers in 
micowave oven treatment. 
趟 b o d y N o r m a l ~ G l y c i n e U ； ^ ^ Citric-buffer 
saline 
下53 ++ + 一 + +++ 一 
c-myc ++ 一 ++ +++ ^Hf 
c 如 + + 一 + + — + + 
c-erbB2 ++ +++ ++ ijlf^： 
+ weak intensity 
++ moderate intensity 
+++ strong intensity 
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Figure 1. Normal cervical epithilum stained with Haematoxylin and Eosin 
(H&E) (Original magnification X 200). 
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Figure 2. A low grade cervical intraepithelial neoplasm (CIN) stained with 
H&E (X 400). 
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Figure 3. A high grade cervical intraepithelial neoplasm (CIN) stained with 
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Figure 5 Adenocarcinoma of cervix with H&E staining (X200). 
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Figure 6. Normal cervical epithelium showing no reactivity ofP53 protein 
(Haematoxylin counterstained. X 200). 
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Figure 7 A low-grade CIN weakly stained for p53 protein by 
immunoperoxidase method. The positive stained cells are within the basal 
layer of the epithelium (Haematoxylin counterstained X 400). 
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Figure 8. p53 positive squamous cell carcinoma of cervix with focal 
nuclear staining pattern (Haematoxylin counterstained X 200). 
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Figure 9. Another cases of moderate differentiated squamous cell 
carcinoma of cervix stained with p53 (X400). 
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Figure 10. Moderately differentiated adenocarcinoma of cervix showing 
P53 immunolocalization in most of the tumour cells. The staining pattern is 
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Figure 14. Adenocarcinoma of cervix showing strong membranous c-erbB2 
staining (Original magnification X 400). 
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Figure 15. Another case of a adenocarcinoma of cervix showing 
membranous c-erbB2 overexpression (X 100). 
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Figure 16. A high grade CIN Shows c-myc protein staining throughout the 
cervical epithelium (X 200). 
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Figure 17. Squamous cell carcinoma of cervix showing predominantly 
nuclear staining of c-myc protein. Note weak cytoplasmic staining ofc-wvc 
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Figure 19. A CIN case showing weak nuclear staining of z-fos protein (X 
200). 
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Figure 20.Poorly differentiated squamous cell carcinoma of cervix showing 
c-fos protein localization (X 400). 
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Figure 21. Another case of c-fos positive squamous cell carcinoma of 
cervix with diffuse nuclear staining pattern (Haematoxylin counterstained X 
200). 
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Figure 22. Adenocarcinoma of cervix showing c-fos protein (X 400). 
103 
Table 4.6 a 
Overexpression of c-myc, c-fos, c-erbhl and p53 oncoprotein and clinico-
pathological parameters of CIN. 
Case no CIN age follow- c-erbBl P53 ~ c - f o s ~ c - m y c ~ 
grade ^ 
c-3 2 42 NED +++ - 一 - -
c-4 3 45 NED + - — - “ ++ 
c-5 1 — 28 N E D + - — - • 
c-6 1 ~ 47 N E D ~ + ~ - ~ - -
c-7 2 41 NED + - + 
c-8 — 2 35— NED ++ - ++ I 
c-10 — 2 39 N E D ~ - ~ - -
c-12 1 38 NED + -
c-14 2 36 NED ~ - " - - I 
c-16 一 3 37— NED ~ ++ " - +++ ++ 
c-17 ~ 3 36 N E D ~ ++ + ~ - + 
c-18~ 3 25 NED +++ + + 
c-19 — 1 36 N E D ~ + - — - -
C-2Q~ 2 29 ~ N E D +++ - ~ - " . 
c-24 — 3 35— NED ~ - " - - + 
c-25 3 36 NED ++ - ++ 
c-28 3 38 NED + - +++ 
c-29 — 1 42 NED +++ + - I 
c-3 2 — 1 31— NED + ++ ~ + 
c-34 — 3 35— NED ~ + " - -
c-35 — 3 32 NED ~ ++ " - - + 
c-36— 3 35 ~ i ^ D + + + 
c-37 3 40 NED ~ ++ " - - + 
s9354~ 1 — 22 NED ++ ~ - ~ ~ 
si 1009 — 3 26 NED ++ + 一 - + 
S9712 2 52 “ NED ++ - - T：^  
S12701 — 2 51 NED ++ - - ~：；：；~~ 
si 1008 1 38 — NED + - - 一 ：；： 
S9711 2 27 NED ++ - _ ~ ： ^ ~ 
S9282 3 ^ 61 Progress ++ I I 
NED: No evidence of disease 
see： Squamous cell carcinoma 
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Table 4.6 a 
Overexpressions of oncoproteins and clinico-pathological parameters in 
cervical cancer. 
Case Age STAGE q ~~H ISTOTrea tmen t Follow-up~ c-erbB2 p53 c-myc 
no 
*244 3b " n T LCNKSCC “ c + R — NED, 7 m ~ 
245 l b LCNKSCC R _ N E D , 2 9 m + + _ _ I ~ 
249 一 57 2b ~ LCKSCC— S + R NED, 25m 
*250 2a "nT LCKSCC S _ NED，27m— +++ ~ I 
*253 60 2a " V LCKSCC “ s “ NED, 25m一 _ ~ ~ 
*256 ~ 5 8 2A ADENO— S — NED，25M一 ± ! ± _ Z Z Z Z ± ~ 
*259 ~ 4 0 2a LCNKSC厂 s N E D , 2 4 m ~ 
260 ~ 6 0 2a LCNKSCC S — NED，23m一 
*265 64— 2a "nT LCKSCC “ s + R NED,27m~" ~ 
266 40 lb 1n~ LCNKSCC" S + R — NED, 25m 
267 ~ 4 r ~ lb p LCNKSCC S " NED, 22m “ 
*275 39 3 ^ p LCNKSCC § + disease, ++ ： ~ 
17m 
*280 61 ~ lb w LCKSCC “ s + R “ NED, 12m j - _ ^ ^ ~ ： 
*282 32— lb . ~ LCKSCC “ S + R NED, 6m一 - h ^ ~ IT" 
*284 51 ~ lb LCKSCC “ s 一 NED，11m ^ _ ~ ： ~ 
*285 68 ~ lb L I T LCNKSCC S + R NED, 15m ++ ： ： 
*290 45 ^ i n L C N K S C C S + R + disease, I ： ^ ^ ^ 
*299 63 ~ 2b m LCNKSCC S + R ~ NED, 11m J H _ ~ 
*303 67~ lb "nT ADSQU “ R ~ NED, 11m ~ -
316 • 4b LCNKSCC R “ DOD，8M一 + I ： 
*304 43 ^ m A D E N O s T r + disease, +++ ： ~ 
8m 
*305 67 “ 2a m LCKSCC S NED, 8m + ~ ；：^ 
*307 60 — 2a m LCKSCC S + R — NED, 8m ： 
*308 68 - lb p LCNKSCC — S ~ ^ D ’ 9m ~ ~ ^ 
*309 75 2b p S NED. 8m ++ … ； “ 
310 72 lb m LCKSCC R NED, 8m ~ ~ ； ： — 
*312 48 lb m LCNKSCC S NED，9m ^ T — 
313 65 3a m LCNKSCC S + R + disease， T ； — 
7m 
314 62 3b m ADSQUA R + disease, ^？； ； ； I T " 
7m 
*317 78 4b p ADENO R D O D ， l m ~ + 一 - — 
*321 60 3b m LCNKSCC R 飞 O D ’ 2m — 
~ m n m LCKSCC C + R + disease, + ； 
6m 
*334 I 42 I lb I m I ADENO s NED, 8m | ++ | _ ‘ ~ T ~ 
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*335 I 26 I lb I m I LCNKSCC s NED, 7m + | - | + 
*336 65 2b ~ LCKSCC — S 7m ++ 
_ J ! 2 3 7 _ ^ 7 _ _ l b m LCNKSCC _ S “ NED, 7m ++ “ ： ~ 
*338 3b pLCNKSCC § + disease, + ： ~ 
7m 
*340 45 3b p L C N K S C C s + R + C + disease， + ： 7 " 
^ 
*343 78 3b p LCKSCC R + disease, +++ ； ： ^ ^ 
8m 
*345 80 3a p ~ ^ R + C + disease, - ： T T T " 
6m 
LCKSCC~ R + C — NED, 7m + ~ ： ~ 
— S 10m + ~ ^ 
6162 30 2b p see — s ~Rec, 8 m " T T T " - + + [ 
2018 36 2b p ADSQU S + R + C Rec, 7m ++ ： 
POD, 18m 
6777 64 2 a m see — s T e c , 11m + + 一 
8112 68 2a m LCNKSCC — S ~ R e c , 5m .+++ ~ 
4773 86 2a w ADENO NO “ P O D , 2 m “ + + " " T " + 
1333 78 3b w ADENO R + disease, ^ ^ ： ~ 
^ 
ADENO ~ c + R " P O D , 19m + + ~ ： ~ 
—肌eno 一 No ~DOD, Im ++ ~ ~ ~ 
6425 44 2b m ADENO S “ NED, 82m “ + ~ T ~ + 
3488 71 Im ++ ~ 
7400 68 3b m ADENO — q ~3 "OD , Im 
1044 48 lb m ADENO 一 S " I j E D , 95m 
_2266 57 lb m ADENO — s " I j E D , 95m 
9249 55 lb m ADENO ~ ~ § T R REC, 57 TT ： T T T 
POD , 58 
1208 I 56 I 2a m LCNKSCC s NED, 6 m | + + | + + | + + 
Grade (G): w，well differentiated; m, moderately differentiated; p, poorly 
differentiated ‘ 
Treatment: surgery (S) included a radical hysterectomy with pelvic and para 
aortic lymphadenctomy, conventional radiation therapy (R), including both 
whole pelvis and intracavitary cesium treatment. Chemotherapy (C). 
Follow-up information includes (1) no evidence of disease (NED), (2) dead 
of disease (DOD), (3) pesistent of the disease (+ disease) and (4)， 
recurrence (Rec) with the interval of time from completion ofintial therapy 
to last evaluation. 
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HISTO ： Histological type 
ADSQU : Adenosquamous cell carcinoma 
ADENO : Adenocarcinoma 
LCNKSCC : Large cell non-keratinized squamous cell carcinoma 
LCKSCC : Large cell keratinized squamous cell carcinoma 
SMC : Small cell carcinoma 
(*) ： With PCR-SSCP analysis of c-myc gene mutation 
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Table 4.6 a 
Overexpression of oncoproteins and clinico-pathological parameters in 
cervical cancer. 
Case Age Stage G “ H I S T O T r e a t m e n t F o l l o w - u p c - f o s 
no 
3b m L C N K S ^ C + R ~ NED, 7m ^ _ “ 
_ J 4 5 _ ^ 7 j _ _ l b m L C N K S ^ R 一 NED，，29m ^ H ^ 
w LCKSCT" S + R ~ NEP] 25m 
250 46 2a m LCKSCT" S 一 NED, 27m - “ 
253 60 2a w LCKSCT" S 一 NED, 25m ^  
256 58 2a ADENO— S NED, 25m “ ++ 
259 40 2a ""jiT" LCNKSCC s NED, 24m + 
260 60 2a LCNKSCC s 一 NED: 23m ++ 
265 2a ~ m ~ LCKSCC— S + R NED,27m 一 ++ 
266 40 lb m LCNKSCC" S + R NED, 25m + 
267 45 lb ""一LCNKSCC — s 
304 43 2a m ADENO S + R + disease, 8m + 
305 67 2a m LCKSCC S ~ NED, 8m -
307 60 2a m ~^KSCC S+ 
308 68 lb " V LCNKSCC S —NED: 9m +++ 
309 75 2b , p _ ADENO § NED, 8m + 
310 72 lb m LCKSCC R 一 
312 48 l b LCNKSCC s N E D : 9 m -
313 65 3a LCNKSCC S + R + disease, 7m + 
_ 3 1 4 _ _ 6 2 3b m ADSQU R ~ disease, 7m ++ 
317 78 4b p ADENO R p p p , i m -
321 60 3b m LCNKSCC R 
•• 2a ~ I IR " LCKSCC C + R ~ disease, 6m ~ + ~ 
334 42 l b m ADENO — s N E D , 8m -
335 26 lb m LCNKSCC S “ NED，7m 一 ~ ~ + ~ ~ 
_ 2 b LCKSCC ~ s _ N E D : 7 m — ~ ~ + 
l b LCNKSCC s 一 N E D : 7 m ~ ~ 
_ 3 3 8 _ ^ ^ ~ LCNKSCC 一 S 
340 45 3b p LCNKSCC " S T R T ^ + disease, 8m ++ 
343 78 3b p LCKSCC ^ + disease’ 8m ++ 
345 80 3a p SMC R + C T d T s e a s e . 6m 
346 76 2a m LCKSCC ~ R + C NED, 7m ~ ： ~ 
12082 I 56 I 2a I m I NKSCC S NED: 6m ++一 
Grade (G): w, well differentiated; m，moderately differentiated and p, 
poorly differentiated. 
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Treatment: surgery (S) includes a radical hysterectomy with pelvic and para 
aortic lymphadenctomy; conventional radiation therapy (R), including both 
whole pelvis and intracavitary cesium treatment. Chemotherapy (C). 
Follow-up information includes (1) no evidence of disease (NED), (2) 
dead of disease(DOD)，(3) pesistent of the disease(+ disease) and (4) 
recurrence (Rec) with the interval of time from completion of intial therapy 
to last evaluation. 
HISTO : Histological type 
ADSQU : Adenosquamous cell carcinoma 
ADENO : Adenocarcinoma 
LCNKSCC : Large cell non-keratinized squamous cell carcinoma 
LCKSCC : Large cell keratinized squamous cell carcinoma 
SMC : Small cell carcinoma 
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(2) Result of c-erbB2 expression 
Of the 57 cervical cancer (38 squamous cell carcinoma (SCC), 15 
adenocarcinoma, 3 adenosquamous and one small cell carcinoma) and 30 
CIN (8 CIN 1, 9 CIN 2 and 13 CIN 3) samples investigated, 
overexpression of the p53 oncoprotein was seen in 22 (38%) carcinomas 
(15 SCC, 5 adenocarcinoma and 2 adenosquamous cell carcinoma) (Table 
4.4) and 6 specimens (20%) of CIN (2 CIN 1 and 4 CIN 3) (Table 4.3). 
Interestingly, there existed a marginal association between p53 protein 
expression in cervical cancer and age of the patients (p=0.05). In the group 
of age over 45, 20 of 44 (45%) specimens were overexpressed of p53 
protein. However, only 2 of 13 (15%) were overexpressed with p53 in the 
group of age equal or below 45 (Table 4.6a). No significant association was 
found between p53 overexpression and clinical parameters (Table 4.6b). 
However, in the group of adenocarcinoma of cervix, 5 out of 15 (33%) 
specimens were overexpressed with the p53 oncoprotein. Among those five 
cases with p53 overexpression, 4 out of 5 (80%) cases were died of the 
disease within one year follow-up (Table 4.6c). 
In this study, overexpression of p53 was found to be inversely 
proportional to pathological grading in the group of squamous cell 
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carcinoma of cervix. There were 2 out of 7 specimens (29%) of poor 
differentiated squamous cell carcinoma positively stained with p53. 
However, 8 of 25 specimens (32%) and 5 of 6 specimens (83%) were 
positively stained with p53 in moderate and well differentiate squamous cell 
carcinoma of cervix, respectively (Table 4.7). However, this result was not 
statistical significance (p=0.056). None of the 8 normal cervical specimens 
was positively stained with p53 protein. 
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Table 4.6 a 
Overexpression of p53 and clinico-pathological parameters in cervical 
cancer. 
Total p53 (+) p53 (-) percentage *P-value 
Stage 1-2 41 14 27 34 NS 
Stage 3-4 16 8 8 50 
Grade 1 10 7 3 ^ NS 
2 36 12 24 33 
3 11 3 8 27 
Age >45 44 ^ 24 45 ^ 
<45 13 2 11 15 
Histo type 
See 38 15 23 39 NS 
Adeno 15 5 10 33 
Adsqu 3 2 1 67 
Smc 1 0 1 0 
Survival 
yes 47 17 30 36 NS 
No 10 5 5 50 
Adsqu: Adenosquamous cell carcinoma 
Adeno: Adenocarcinoma 
Lcnkscc: Large cell non-keratinized squamous cell carcinoma 
Lckscc: Large cell keratinized squamous cell carcinoma 
Smc: Small cell carcinoma 
NS: No statistic significance 
* Chi-square test 
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Table 4.6 b Overexpression of p53 and clinico-pathological parameters 
in cervical cancer. 
p53 Total *P-value 
Negative + ++/ +++ 
Stage 
1 13 4 1 18 
2 14 6 3 23 NS 
3-4 8 5 3 16 
GRADE 
1 3 4 3 10 
2 24 9 3 36 NS 
3 8 2 1 11 
HISTO 
Adeno 10 1 4 15 
Adsqu 1 2 0 3 NS 
See 23 12 3 38 
Smc 1 0 0 1 
SURVIVAL 
No 5 2 3 10 NS 
Yes ^ n 4 47 
Adsqu: Adenosquamous cell carcinoma 
Adeno: Adenocarcinoma 
Lcnkscc: Large cell non-keratinized squamous cell carcinoma 
Lckscc: Large cell keratinized squamous cell carcinoma 
Smc: Small cell carcinoma 
*： Fisher's Exact test 
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Table 4.6c Association of expression p53 protein with clinical and 
pathological parameters in cervical adenocarinoma. 
Total p53(-) p53(+) Persenta^e *P-value 
Stage 1-2 9 7 2 22 NS 
3-4 6 3 3 50 
Grade 1 4 2 2 50 T^ 
2 9 7 2 22 
3 2 1 1 50 
Age >45 12 7 5 42 NS 
<45 3 3 0 0 
Survival Y 8 7 1 12^ 0 . 0 6 7 ^ 
N 7 3 4 57 • 
* Chi-square test 
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Table 4.6 a 
Relationship between p53 expression and clinico-pathological parameters in 
squamous cell carcinoma of cervix. 
Total p53 (+) p53 (-) Percentage *P-value 
Stage 1-2 30 H 19 37 
3-4 8 4 4 50 
Grade 1 6 5 1 83 0.056 
2 25 8 17 32 
3 7 2 5 29 
Age >45 29 13 16 45 NS 
<45 9 2 17 n 
* Chi-square test 
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(2) Result of c-erbB2 expression 
Of the 57 cervical cancer and 30 CIN specimens investigated, over-
expression of the c-erbm oncoprotein was seen in 54 (94%) cervical 
cancer (36 see, 15 adenocarcinoma and 3 adenosquamous cell carcinoma) 
(Table 4.4) and 26 (87%) cases of CIN (8 CIN 1, 7 CIN 2, 11 CIN 3) 
(Table 4.3). The only case of small cell carcinoma did not show any 
immunoreactivity. No association was found between the expression of this 
oncoprotein and tumour stage, tumour grade and survival (Table 4.8). 
However, all four specimens with early recurrence within one year were 
moderately or strongly overexpressed with c-erbBl protein (Table 4.4). 
In addition, the c-erbB2 protein was detected in 3 normal cervical 
control specimens. 
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Table 4.8 Overexpression of c-erbB2 and clinico-pathological 
parameters in cervical cancer. 
c-erbm Total *P-value 
Negative/ + +++ 
Stage 
1 6 6 6 18 
2 6 8 9 23 NS 
3-4 6 6 4 16 
GRADE 
1 2 6 2 10 
2 11 12 13 36 NS 
3 5 2 4 11 
HISTO 
Adeno 2 9 4 15 
Adsqu 0 1 2 3 NS 
See 15 10 13 38 
Smc 1 0 0 1 
SURVIVAL ‘ 
No 2 6 2 10 NS 
Yes U \1_ ^ 
HISTO: Histological type 
Adsqu: Adenosquamous cell carcinoma 
Adeno: Adenocarcinoma 
Lcnkscc: Large cell non-keratinized squamous cell carcinoma 
Lckscc: Large cell keratinized squamous cell carcinoma 
Smc: Small cell carcinoma 
*: Fisher's Exact test 
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(2) Result of c-erbB2 expression 
Of the 57 specimens of cervical cancer and 30 specimens of CIN 
investigated by immunohistochemistry, 47 (82%) (29 SCC, 15 
adenocarcinoma, 2 adenosquamous and 1 small cell carcinoma) cancer 
specimens and 20 of 30 (67%) (three CIN 1’ 4 CIN 2 and 13 CIN 3) of 
CIN specimens were c-myc protein positive (Table 4.3，4.4). The 
expression of c-myc protein had a marginal association with pathological 
grade in cervical cancer (p=0.05) (Table 4.9). In well and moderate 
differentiated cervical carcinoma, only 2 out of 10 (20%) and 10 out of 36 
(28%) specimens were overexpressed with Q,-myc protein (++/+++) 
respectively. However, c-myc protein was detected in 64% of the poor 
differentiated carcinoma (p<0.05) (Table 4.9). 
In the group of squamous cell carcinoma of cervix, the expression 
of c-myc was associated with clinical stage (FIGO). 25 cases (83%) of 
squamous cell carcinoma of cervix in the group of FIGO stage 1-2 were 
overexpressed with c-myc but only 4 of 8 (50%) had omyc overexpression 
in stage 3-4 (p<0.05) (Table 4.10). 
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There was no significant association between c-myc overexpression 
and CIN grading. Two cases of normal cervical specimens were also 
positively stained with c-myc protein. 
In this study of c-myc gene mutation, none of the 30 invasive 
cervical cancer was demonstrated with c-myc gene mutation by PCR-SSCP 
analysis. However, 24 of the 30 specimens were presented with c-myc 
overexpression by immunohistochemical study. 
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Table 4.9 Overexpression of c-myc and clinico-pathological 
parameters in cervical cancer. 
Total c-myc c-myc Percentage *P-value 
Negative/ + ++/ +++ 
Stage 1-2 41 30 11 27 NS 
3-4 16 8 8 50 
Grade 1 10 8 2 ^ ^ 
2 36 26 10 28 
3 11 4 7 64 
Age>45 44 29 15 M “ 
<45 13 9 4 31 
HISTO ^ ^ S ~ 
See 38 29 9 24 
Adeno 15 8 7 47 
Adsqu 3 1 2 67 
Smc 1 1 0 0 
HISTO: Histological type 
Adsqu: Adenosquamous cell carcinoma 
Adeno: Adenocarcinoma 
Lcnkscc: Large cell non-keratinized squamous cell carcinoma 
Lckscc: Large cell keratinized squamous cell carcinoma 
Smc: Small cell carcinoma 
*: Chi-square test 
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Table 4.10 Overexpression of c-myc and clinico-pathological 
parameters in squamous cell carcinoma of the cervix. 
Total c-myc c-myc Percentage *P-vaule 
(+) (-) 
Stage 1-2 30 25 5 83 <0.05 
3-4 8 4 4 50 
Grade 1 6 5 1 83 NS 
2 25 19 6 76 
3 7 5 2 71 
Age >45 ^ ^ 6 ^ 
<45 9 6 3 ^ 
* Chi-square test 
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(2) Result of c-erbB2 expression 
In addition, the expression of c-fos oncoprotein in 33 specimens of 
cervical cancer (26 SCC, 5 adenocarcinoma, 1 adenosquamous cell 
carcinoma and 1 small cell carcinoma) and 30 specimens of CIN (8 CIN 1， 
9 CIN 2 and 13 CIN 3)were immunohistochemically investigated. 20 of 33 
(61%) (16 SCC, 3 adenocarcinoma and 1 adenosquamous cell carcinoma) 
cervical cancer revealed c-fos (Table 4.5 & 4.11) overexpression. There 
was no apparent relationship between overexpression of z-fos protein and 
the clinical or pathological parameters in all cervical cancer specimens 
(Table 4.11). Only 3 cases of CIN overexpressed with c-fos protein and all 
of them were in high grade CIN (Table 4.3). 
None of 8 normal control cervical specimens was stained with the 
c-fos protein. 
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Table 4.11 Overexpression of c-fos and clinico-pathological parameters 
in cervical cancer. 
c-fos ^ T o t a l *P-value 
Negative + ++/ +++ 
Stage 
1 3 3 3 9 
2 6 5 4 15 NS 
3-4 4 1 4 9 
GRADE 
1 2 1 0 3 
2 9 1 6 22 NS 
3 2 1 5 8 • 
HISTO 
Adeno 2 2 1 5 
Adsqu 0 0 1 1 NS 
See 10 7 9 26 
Smc 1 0 0 1 
SURVIVAL 
No 2 0 0 2 NS 
Yes H 9 U 3J 
HISTO: Histological type 
Adsqu: Adenosquamous cell carcinoma 
Adeno: Adenocarcinoma 
Lcnkscc: Large cell non-keratinized squamous cell carcinoma 
Lckscc: Large cell keratinized squamous cell carcinoma 
Smc: Small cell carcinoma 
NS: No statistic significance 
*： Fisher's Exact test 
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(5) Relationship among different oncogenes overexpressions 
Comparing the overexpression of different oncogenes, No 
significant association was found among the four oncoproteins 
overexpressions. However, it was found that overexpression of c-fos 
protein co-existed with overexpression of the c-erbB2 protein. Of the 20 
cases overexpressed with o-fos protein, all of them co-existed with c-erbB2 
protein overexpression (Table 4.12). 
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Table 4.12 Association among overexpression of the different 
oncogenes and tumour suppressor gene products. 
Total p53 (+) p53 (-) 
c-myc (+) 47 19 28 
c-myc (-) 10 3 7 
c-erbB2 (+) 54 22 32 
c-erbB2 (-) 3 0 3 
c-fos (+) 20 9 11 
c-fos (-) 13 5 8 
Total c-myc (+) c-myc (-) 
c-erbb2(+) 54 44 10 
c-erbb2 (-) 3 3 0 
c-fos (+) 20 16 4 
c-fos (-) 13 12 1 
Total c-erbm (+) c-erbB2 
c-fos (+) 20 20 0 
c-fos (-) U n 2 
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(6) Result of PCR-SSCP 
For screening of c-myc gene mutation, a hot-spot mutation exon 2 
of c-myc was examined by PCR-SSCP. No mutation was observed in all 30 
specimens tested. However, 24 (80%) of the 30 cases were also studied by 





Generally, formalin-fixed, paraffin-embedded materials are not 
suitable for immunhistochemical demonstration of some antigens (Fox et 
al., 1985). Several methods have been developed to retrieve the 
antigenicity. Pretreatment of tissue sections by proteolytic enzymes (trysin, 
pepsin etc.) has been used to restore the accessibility of antibodies to 
epitopes masked by fixation ( Finley and Petrusz 1982) but it may not be 
suitable in all kinds of antibodies. The enzymatic pretreatment with low 
concentration and /or short time treatment is inadequate to unmask antigens 
but prolonged exposure to the enzymes may reduce the immunoreactivity 
because of overdigestion. The morphology of enzymatic pre-treatment of 
section is usually bad and may result in difficulty in scoring. Another 
method using wet antoclave antigen retrieval was also reported to have 
good result. However, this method is not easy to handle (Piffko et al., 
1995). 
Recently, Shi, Key and Kalra (1991) demonstrated that significant 
antigen retrieval could be achieved in formalin-fixed, paraffin-embedded 
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tissue sections by microwave oven heating of the tissue sections. The 
mechanism of microwave heating is still unclear but it may be due to 
increased molecular agitation by raising the temperature. This can cause 
protein denaturation and also break peptide bonds at aspartyl residues (Wu 
et al., 1992). Morgan et al. (1994) also suggested that a tight complex of 
calcium ions or other divalent metal cations were formed with protein 
during formaldehyde tissue fixation. With the help of high temperature and 
exposure to a calcium chelating or precipitating salt solution in microwave 
oven pretreatment, tightly complexed calcium ions are extracted from the 
tissue to re-exposure antigenic site and increase immunosensitivity (Morgan 
et al., 1994). 
Kerns et al. (1992) suggested that p53 overexpression could be 
demonstrated only in fresh-frozen tissues previously. This was in keeping 
with the result in this study that p53 overexpression could not be 
demonstrated in paraffin sections by using enyzmatic pretreatment (trysine 
and pronase). However, p53 overexpression could be demonstrated by 
using microwave antigen retrieval. 
In this study, the staining pattern of Q-myc protein was mainly 
nuclear. However, weak cytoplasmic staining also occured in some 
specimens. In the immunohistochemical studies of z-myc oncoprotien, 
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Loke and his colleague (1988) suggested that its detected localization 
varied with the fixation methods. Formalin fixed and paraffin embedded 
tissues were described to accompany with reduction or loss of nuclear 
staining and the presence of cytoplasmic staining (Loke et al, 1988). 
William and his colleague (1990) believed that nuclear staining of c-myc 
protein in carcinoma might be more labile for nonspecific reasons such as 
differences in rate of change of pH, ATP-concentration, release of 
proteolytic enzymes or other factors. The appearance of cytoplasmic 
staining of c-myc oncoprotein might be due to tissue fixation method and 
processing artifact (Jones et al., 1987) or due to cross-reaction of the 
monoclonal antibody with an unrelated antigen which shared an epitope 
with the c-myc protein (Ciclitira et al, 1987). In this study, microwave 
pretreatment usually showed more nuclear staining and less nonspecific 
background staining while sections without microwave pretreatment 
showed some cytoplasmic staining of c-myc and less nuclear staining. It 
suggested that antibody permeability or antigen re-exposure could be 
enhanced by microwave antigen retreival method. 
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p53 and cervical neoplasm 
The p53 gene is a tumour suppressor gene. It encodes a 53 
kilodalton nuclear phosphoprotein and locates on the short arm of 
chromosome 17 (Finlay et al., 1989; Diller et al., 1990). p53 plays a role in 
the prevention of genomic instability. DNA damage will result in the 
increase of p53 protein which blocks along the cell cycle in the Gl/S phase 
checkpoint and finally results in DNA repair or apoptosis (Yonish-Rouach 
et al., 1991). Alteration of the p53 gene may result in lost of tumour 
suppresser function of the gene and unlimited cell proliferation. Wild-type 
p53 has a short half.life of about 5 to 20 minutes and is usually undetectable 
by immunohistochemistry (Reich et al., 1983). However, mutations or 
other mechanisms may inactivate the gene, stabilize the p53 protein and 
increase its half life to four to eight hours so that it can be detected by 
immunohistochemistry (Halevy et al., 1989). Overexpression of mutant p53 
is a common occurrence in many malignant tumours such as melanomas 
(Stretch et al., 1991), soft tissue sarcomas (Porter et al., 1992), and 
carcinomas of breast (Cattoretti et al., 1988), colon (Van den Berg et al., 
1989), stomach (Seruca et al., 1992), lung (Camano et al., 1991), testis 
(Barthkova et al., 1991)，ovary (Marks, Davidoff and Kerns, 1991) and 
pancreas (Barton et al., 1991). In this study, an incidence of 22 of 57 
130 
(38%) in cervical cancers and 6 of 30 (20%) in CIN specimens were 
immunohistochemically detected with p53 protein and the overexpression 
was restricted to the nuclei. This finding of CIN specimens was contrast to 
Jeffers et al. (1994) who demonstrated a relatively higher detection rate. In 
their study, 13 of 22 (59%) CIN 3 and 3 of 14 (21%) CIN 2 and 5 of 13 
(38%) CIN 1 specimens were overexpressed with the p53 protein using 
microwave antigen retrieval. 
The results in this study showed that normal cervical epithelium in 
all cases was not stained with p53 protein. This confirmed (Inoue et al., 
1994; Cardillo et al., 1993; Reich et al., 1983; Holm et al., 1993) that the 
normal p53 protein was too low to be detected immunohistochemically in 
steady-state level. The locations of p53 positive nuclei in CIN were mainly 
within the epithelium and the basal area. The p53 positive rate was low in 
CIN cases but apparently increased in invasive cervical cancers. The study 
demonstrated that p53 overexpression might be involved in the event of 
the neoplastic progression of cervical cancer because it was detected in 
none of the normal cervical specimens but found in 6 of 30 (20%) of CIN 
and in 22 of 57 (38%) of cervical cancer. A similar result in p53 
immunodetection was observed by Cardillo et al. ( 1993). In addition, this 
study showed a fewer number of p53 positive specimens in adenocarcinoma 
than that in squamous cell carcinoma of cervix. This result was in 
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agreement with a previous report by Holm et al. (1993). In their study, 
62% of invasive squamous cell carcinomas and 11 % of adenocarcinoma 
were found overexpressed with the p53 protein. The study of other 
tumours such as lung cancer also showed that overexpression of p53 was 
more frequently associated with squamous cell carcinoma than 
adenocarcinoma (Iggo et al., 1990). These results suggested that p53 
overexpression might play a more important role in the pathogenesis of 
squamous cell carcinoma than adenocarcinoma. 
In this study, no significant association was found between p53 
immunoreactivity in carcinoma and prognostic parameters such as 
pathological grade of differentiation and clinical stage (FIGO). However, 
there was a marginal association with age of patients (p=0.05) because the 
incidence of p53 overexpression was higher in patients of age over 45 than 
that of below 45. For p53 was suggested to function as a molecular 
policeman responsive to DNA damage, if a cell whose p53 pathway has 
been inactivated by mutation or by binding to other proteins or by other 
mechanisms is damaged, it will still be able to survive and divide 
because the p53 checkpoint will not function. Aging effect will result in 
loss of function of immunoresponse reaction and may also lead to loss of 
tumour suppressor function. This may explain why tumourogenesis is 
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usually more frequently in elderly. In addition, a reverse proportion was 
found between p53 overexpression and squamous cell carcinoma of cervix. 
It might suggest that p53 overexpression was associated with tumour 
differentiation in cervical cancer. However, this result was not satistical 
significance (p=0.056). p53 overexpression was found to have different 
degrees of prognostic significance in different cancers. The prognostic 
value of p53 overexpression has been suggested in breast cancer (Isola et 
al., 1992; Thor et al., 1992), colon cancer (Scott et al, 1991), lung cancer 
(Mclaren et al., 1992) and ovarian cancer (Mark et al., 1991). However, 
p53 overexpression is also found to have no prognostic significance in 
laryngeal squamous cell carcinoma (Nadal et al., 1995) and in head and 
neck squamous cell carcinoma (Field et al., 1993). In this study, in the 
group of adenocarcinoma of cervix, 5 out of 15 (33%) specimens were 
overexpressed with the p53 oncoprotein. Among those five cases with p53 
overexpression, 4 out of 5 (80%) cases were died of the disease within one 
year follow-up. It might suggest that overexpression of the p53 protein may 
associate with poor outcome in cervical adenocarcinoma. 
c-erbB2 and cervical neoplasm 
c-erbB2 gene is a proto-oncogene which encodes a 185-190 
kilodalton glycoprotein molecule that functions as growth factors, 
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epidermal growth factor receptors and cytoplasmic second messengers 
(Yamamoto et al., 1986). The c-erbBl gene functions in cell growth and 
differentiation. c-erbBl protein was well studied in breast carcinoma and its 
positivity indicated more aggressive behavior and correlated with poor 
prognosis of the disease (Slamon et al., 1989; Walker et al., 1989; Corbett 
et al., 1990). Brumm et al. (1990) found that c-erbBl protein showed 
weakly positive staining with the basal layer of squamous epithelial in 
normal cervix and some cell layers of endocervix glands but was usually 
strongly overexpressed in CIN 3 and invasive cervical carcinoma. 
In the detection of c - e M 2 expression in 26 cervical carcinoma, 
Berchuck et al. (1990) used frozen rather than formalin fixed tissue and 
they found that all 26 cervical cancer specimens overexpressed with the c-
^rbB2 protein. However, Suo and his colleagues (1992) showed no c-
erbBl immunoreactivity in all 47 squamous cell carcinomas of cervix. In 
other studies, Hale and his co-workers (1992) only detected c-erhB2 onco-
protein positivity in 24 out of 62 (38%) cervical cancers although Kihana 
et al. (1994) detected 34 of 44 (77%) cervical carcinoma with the c-erbB2 
protein overexpression. As a result, it showed that the results of previous 
findings ofc-erbB2 overexpression in cervical cancer were inconsistent. In 
this study, with the technique of microwave antigen retrieval, the result 
showed an incidence of c-erbB2 overexpression in 26 out of 30 (87%) CIN 
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specimens (mostly weak to moderate overexpression) and positivity in 54 
out of 57 (94%) of invasive carcinoma of cervix (mostly strong 
overexpression). This suggested that c-erbB2 overexpression might be 
involved in the pathogenesis of cervical cancer. The result supported the 
finding of Berchuck et al. (1990) which indicated a higher positivity than 
the others by using frozen section rather than paraffin section in 
immunhistochemical staining. The result might also suggest that most c-
erbB2 proteins in cervical cancer was not destroyed during formalin-
fixation paraffin embedding processes. This c-erbB2 proteins was only 
masked by formalin fixation but recovered after microwave retrieval of 
antigens. 
In the view of prognosis value, overexpression of c-erhB2 protein 
in different cancers was reported by many studies. It was found to 
associate with poor prognosis of breast cancer (Slamon et al., 1989; 
Walker et al., 1989; Corbett et al., 1990) and associate with a poor 
prognosis in advanced stage disease in endometrial cancer (Berchuck et al., 
1991). However, it did not have prognostic value in ovarian neoplasms 
(Slammon et al., 1989; Zhang et al, 1989; Haldane et al., 1990; Wilkinson 
et al., 1991) and salivary gland adenocarcinoma (Field et al., 1989; Sugano 
et al, 1992). In addition, prognostic value was found in uterine cervical 
cancer (Hale et al., 1992). Hale and his colleagues (1992) 
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immunohistochemically studied the expression and prognostic importance 
of c-erbB2 protein in sixty-two cases of Stage 1B/2A cervical carcinoma 
and followed up of at least five years duration. Their result showed that 
membranous staining was seen in 38.7% of specimens and there was a 
strong correlation with poor survival. Kinhana et al. (1994) also found the 
similar result of poor prognosis in patients strongly overexpressed with c-
erbB2 protein in cervical adenocarcinoma. In this study, strong c-erbB2 
overexpression might also have prognostic significance. All four cases of 
early recurrence of cervical cancer (follow up within one year after 
completion of initial therapy) were strongly (++/+++) overexpressed of c-
erbBl oncoprotein. 
Moreover, no significant relationship was found between z-erbBl 
overexpression and pathological grade in this study. However, c-erbB2 
gene overexpression might associate with histological type. Although high 
incidence rate was detected with c-erbB2 overexpression in cervical cancer 
in this study, there was no immunoreactivity with c-erbB2 in the case of 
small cell carcinoma of cervix. This result supported the finding of Holm et 
al. (1993). In their study, all 28 specimens of small cell carcinoma of cervix 
showed no immunoreactivity of the c-erbB2 protein. However, only one 
case of small cell carcinoma was tested in this study. 
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c-myc and cervical neoplasm 
c-myc protein under normal conditions is implicated in the control 
of cells proliferation (Pfeifer-Ohlsson.,1985), transformation and 
differentiation (Schweinfest et al., 1988). It was amplified in many tumours, 
particularly small cell lung carcinoma (SCLC) (Gazdar et al., 1985), breast 
(Guerin et al., 1988 ； Tsuda et al., 1989) and cervical carcinoma (Ocadiz et 
al., 1987). It was also proposed that any c-myc protein malfunction might 
involve in the early stages of mammary carcinogenesis (Escot et al., 1993) 
and lead to the development of neoplasia (Escot et al., 1993). 
Several other studies found that c-myc overexpression progressed 
from normal tissue through preinvasive lesion to invasive carcinoma in 
some tissues including colonic carcinoma (Stewart et al., 1986), familial 
adenomatous neoplasia (Subdaresan et al., 1987)，anal squamous neoplasia 
(Ogunbiyi et al., 1993) and both structural alteration and overexpression in 
progression of cervical cancer (Riou et al., 1987; Pinion et al., 1991). 
However, other studies failed to show any relation between z-myc 
overexpression and the grade of cervical neoplasia (Hendy-Ibbs et al., 
1987; Hughes et al., 1989). Mechanisms were identified in the deregulation 
of c-myc expression in tumours and tumour cell lines. These mechanisms 
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included gene amplification, translocation, mutation and increased 
production of c-myc RNA by proviral insertion (Depinho et al., 1991). 
In this study, 20 of 30 (67%) of CIN (3 CIN 1,4 CIN 2 and 13 CIN 
3) and 47 of 57 (82%) (29 SCC, 15 Adenocarcinoma, 2 adenosquamous 
and 1 small cell carcinoma) invasive cervical cancer specimens were 
overexpressed with the c-myc protein. In addition, c-myc oncoprotein 
strongly overexpressed in invasive cervical cancer but was only weak to 
moderate overexpression in most of the CIN specimens. These results 
suggested that c-myc oncoprotein overexpression might be implicated in 
the pathogenesis of cervical cancer. Moreover, c-myc overexpression was 
also associated with pathological grade of cervical cancer in this study. In 
well and moderate differentiated cervical carcinoma, only 20% and 28% of 
specimens were strongly (++/+++) overexpressed of c-myc protein, 
respectively. However, c-myc protein was detected in 64% of the poorly 
differentiated carcinoma (p<0.05). Therefore, alteration of c-myc gene 
expression might be responsible in part for the poorly differentiated state in 
cervical cancer. 
In the group of squamous cell carcinoma of cervix, the expression 
of c-myc was associated with clinical stage (FIGO). 25 cases (83%) of 
squamous cell carcinoma of cervix in the group of clinical stage (FIGO) 1-2 
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were overexpressed with c-myc protein but only 4 of 8 (50%) had c-myc 
overexpression in stage 3-4 (p<0.05). This result showed with statistically 
significant (p< 0.05) that c-myc overexpression consisted of a negative 
association with clinical stage (FIGO) in the group of squamous cell 
carcinoma. 
The PCR-SSCP method was well established to be a sensitive 
method in screening gene mutation (Sarkar et al., 1992; Schneider et al., 
1994). In this study, using PCR-SSCP analysis, none of the 30 invasive 
cervical cancer showed c-myc gene mutation. However, 24 of the 30 
specimens existed c-myc overexpression by immunohistochemical study. 
Therefore c-myc protein overexpression might not relate to c-myc gene 
mutation in cervical cancer. Symonds et al. (1989) suggested that although 
c-myc protein overexpression was associated with the occurrence of many 
types of tumours, no c-myc oncogene mutation which might enhance 
pathogenicity was required. The result of this study was also in keeping 
with Symonds et al. (1989) that c-myc protein overexpression rather than c-
— c gene mutation played the important role in the pathogenesis of 
cervical cancer. 
It is noted that PCR-SSCP is just a method for screening gene 
mutation. The detection sensitivity of PCR-SSCP depended on the size of 
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PCR fragment. Sarkar and co-workers (1992) showed in a systematic study 
that, under optimized conditions, the PCR-SSCP detected 92% of all 
mutation in 183 bp fragment. However, only 59 % of all mutation was 
detected when the PCR fragment was 307 bp. The length of exons in c-
myc gene was 208 bp in 2AB, 189 bp in 2CD and 207 bp in 2EF. The 
sensitive rate of PCR-SSCP was decreased apparently when the length of 
exon more than 200 bp (Sarkar et al., 1992). As a result, some mutation 
might not be detected. In addition, only a small number of cervical 
carcinoma specimens was tested in this study. Another less happening 
explaination is that the z-myc gene mutation in the specimens of this study 
may be beyond the hot-spot region. A further study using more sensitive 
methods such as RNA-SSCP (Sarkar et al., 1992; Danenberg et al., 1992) 
or direct sequencing in order to confirm the absence of gene mutation in 
cervical cancer might be useful. Nevertheless, the result of this study 
suggested that the c-myc gene mutation did not significantly relate to 
cervical cancer. 
c - f e and cervical neoplasm 
Overexpression of c-fos oncoprotein has been reported in human 
osteosarcomas (Wu et al., 1990), hepatocarcinoma (Arbuthnot et al., 
1991)，colorectal adenomas and carcinoma (Magrisso et al., 1993), lung 
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cancer (Volm，Drings and Wodrich, 1993; Volm, Efferth and Mattern, 
1992) and breast carcinoma (Walker et al., 1991). c-fos overexpression was 
also found to occur in cervical cancer (Petrov et al., 1994). However, the 
association between c-fos oncoprotein overexpression and the development 
of cervical cancer has not previously been extensively investigated. 
In this study, 3 (10%) out of 30 cases with CIN and 20 (60%) out 
of 33 cases with cervical cancer were immunohistochemically found to 
overexpress with the c-fos protein. The staining pattern was confined to the 
tumour cells nuclei and none of the 8 normal control specimens was 
stained. In this study, c-fos oncoprotein overexpression was not related to 
tumour grade, FIGO stage and survival rate in cervical cancer. In the cases 
of CIN, c-fos protein overexpression was associated with CIN grading. 
The three specimens immunohistochemically found to have c-fos 
oncoprotein overexpression were all in high CIN grades (one CIN 2 and 
two CIN 3). These results suggested that c-fos overexpression might be a 
late event in the evolution of CIN. Moreover, the c-fos protein increased 
apparently from preinvasive (CIN) (10%) to invasive cervical cancer 
(6O0/0). This result suggested that c-fos overexpression might be an 
important event in malignant transformation. 
Normal control 
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In this study, 3 out of 8 cases of normal cervical specimens were 
also positively stained with c-erbm protein. In addition, 2 other cases 
were positively stained with the c-myc protein. However, the staining 
patterns were all relatively weak and mainly in the basal area of the cervical 
epithelium. This finding of c-erbB2 immunohistochemically stained in 
normal cervical epithelium has been reported by other studies (Kihana et 
al., 1994). Q-erbm overexpression had been found in undifferentiated 
keratinocytes in squamous metaplasia and condyloma (Berchuck et al., 
1990). In addition, c-myc has been positively stained in normal and 
hyperplastic endometrium of uterus (Bai et al., 1994), in normal testicular 
tissue (Sikora et al.； 1985). The appearance of staining of c-myc in normal 
oncoprotein were also suggested be due to cross-reaction of the 
monoclonal antibody with an unrelated antigen which shared an epitope 
with the c-myc protein (Ciclitira et al., 1987). Moreover, in this study the 
normal control specimens were collected from patients suffering from 
uterine leiomyoma. The proliferated state of this benign disease may also 
activated certain oncogenes by other unknown mechanism. 
Oncogene co-expression 
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There were limited report about oncogene co-expression in cervical 
cancer. Significant co-expression of c-erbB2 proto-oncogene activation and 
p53 tumour suppressor gene inactivation have been found in breast (Isola et 
al.，1992), bladder (Wright et al., 1991) and gall bladder (Kamel et al., 
1993) cancers. In addition, expression of c-myc proteins was found to be 
induced by growth factors such as estrogens in breast cancer (Dubik and 
Shiu，1992) and also interrelated with expression of other growth factor 
receptor such as c-erbB2 in transitional cell bladder tumours (Lipponen, 
1995). Coexpression of c-erbB2 and p53 in breast cancer might also 
associate with shorter disease free survival in node-positive breast cancer 
patient (Wiltschke et al., 1994). However, Sato et al. (1991) reported that 
there was no relationship between expressions of c-myc and c-erbB2 in 
cervical adenocarcinoma. 
Comparing the overexpression of different oncogenes, no significant 
association was found among all four oncoproteins overexpressions in this 
study. However, it was found that overexpression of c-fos protein co-
existed with overexpression of the c-erhB2 protein. Of the 20 cases 
overexpressed with c-fos protein, all of them co-existed with c-erhB2 
protein overexpression. 
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Proto-oncogenes have been found to encode proteins that fall into 
four major classes based on their functions. These include growth factors, 
growth factor receptors, cytoplasmic signal transduction molecules and 
nuclear transcription factors. Growth factors are secreted molecules that 
interact with growth factor receptors expressed on the cell surfaces. 
Interaction of these molecules transmits a signal to the cell nucleus and 
results in cellular proliferation. Therefore, the signal must involve molecules 
in the cytoplasm (cytoplasmic signal transaction molecules) to send the 
appropriate message to nuclear proteins and control the nuclear functions 
necessary for DNA synthesis. 
Different types of oncogenes might participate in different way in 
cellular control systems through multiple parallel pathways. It is this 
multiplicity that makes tumourogenesis such a complex matter and that 
many genetic alternation might be necessary to produce a cancer. To 
convert a normal cell to transformed state, more than one oncogenes may 
act in collaborations (land et al., 1983; Rasko and Downes, 1995). In 
general, the combination of one nuclear-acting oncogene and one 
cytoplasmic-acting oncogene works co-operatatively in converting a 
normal cell to a transformed state. The process of gene amplification 
usually involves co-amplification of extensive regions of DNA that share a 




Development and progression of cancer are well known to be a 
multistep processes. Although there has been only limited knowledge 
about oncogene and tumour suppressor gene but more and more studies 
come out in recent years providing considerable evidences supporting 
oncogenes activation and tumour suppressor genes inactivation in the 
development of cervical cancer. In this study, overexpressions of c-erbB2 
and c-myc proteins were found to relate to the pathogenesis of cervical 
carcinomas while overexpression of p53 and c-fos were associated with the 
progression of cervical carcinomas. The co-existence of overexpression of 
c-/ay and c-erbB2 might suggest that overexpression of one oncoprotein 
might associate with the overexpression of the other. 
Although overexpression of oncoproteins were found to associated 
with initiation and progression of cervical cancer. Variation of results were 
found in different studies. This may be attributed to different methods of 
analysis and tissue fixation which may influence antigen preservation. In 
addition, the small number of samples studied might also introduce the 
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possibility of sampling error. With the help of microwave antigen-retrieval 
method as described by Shi, Key & Kalra (1991)，immunohistochemical 
detection of p53, c-myc and z-fos proteins overexpressions could 
be improved because of the re-exposure of formalin fixed and masked 
antigens. In the study of prognostic value, since only paraffin blocks might 
be provided, the availability of reliable antigen retrieval techniques might 
eliminate some of the discrepancies that were attributed to different 
fixation. As a result, more formalin fixed and paraffin embedded materials 
from a variety of tumours with known clinical outcomes could be available 
for further studies. More knowledges about the prognostic value of these 
oncogenes and tumour suppressor genes could be provided in the near 
future. 
Moreover, HPV might also play a role in the carcinogensis of 
cervical cancer (Zur Hansen, 1980，1989). However, HPV infection alone 
was insufficient to bring about the fully malignant phenotype. One 
mechanism by which HPV inducing neoplasia was through integration into 
cellular DNA in the proximity of c-myc and induction of c-myc expression. 
Another mechanism of the tumour inducing properties of HPV might relate 
to inhibition of the tumour suppressor function of p53 gene (Chen et al., 
1993). However, HPV typing was not prepared in this study and further 
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study to learn more about any relationship among this infectious agent, 
oncogenes and tumour suppressor genes might be required. 
The overexpression of c-erhB2 and c-myc in both preinvasive and 
early recurrence of cervical cancer in this study indicated that the 
determination of oncogene overexpressions might be a useful tool for 
screening the high risk group of cervical precancerous lesions and early 
recurrence. In addition, overexpression of the p53 protein might be 
associated with poor outcome in the group of cervical adenocarcinoma. 
However, only a small number of cases and relatively short duration 
of follow up were' studied in the present study. A further study with 
sufficient follow-up time and more samples might be required to confirm 
the potential value of examination of oncogenes and tumour suppressor 
genes in early diagnosis and prognosis of cervical neoplasm. In addition, 
raised serum level of certain oncoproteins were proved to correlate with 
tumour spreading including tumour size and nodal involvement in breast 
cancer (Fontana et al., 1994). A further study including the raised serum 
level of certain oncoproteins combined with the results of 
immunohistochemical staining may obtain more information about 
oncogenes and cervical cancer. 
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Oncogene activation may be presented in different molecular levels. 
Oncogene overexpression only suggests that gene product is increased. Any 
alteration of the proto-oncogene can result in gene overexpression. So, 
fbrther studies is required to elucidate the type of gene alternation which 
causes the overexpressions of these oncogene and tumour suppressor gene 
products. In addition, the significance of any gene alteration and its 
application to diagnosis，prognosis and possible gene therapy would be 
another important subject to be studied. 
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